Activated pancreatic stellate cells regulate

macrophage polarization and function in tumor microenvironment by Mustafa, Shakhawan
  
Dissertation 
submitted to the 
Combined Faculty of Natural Sciences and Mathematics 
of the Ruperto Carola University Heidelberg, Germany 
for the degree of 
Doctor of Natural Sciences 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presented by 
MSc in molecular biotechnology, Shakhawan Mustafa  
born in: Sulaimani / Iraq 
Oral examination: 13.06.2018 
 
 
 
 
 
 
Activated pancreatic stellate cells regulate  
macrophage polarization and function in tumor 
microenvironment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referees:   
Prof. Dr. Gert Fricker 
Prof. Dr. Aurelio Teleman 
 
 
 
 1 
 
1. Table of contents 
 
1. TABLE OF CONTENTS .............................................................................................................. 1 
2. LIST OF FIGURES ...................................................................................................................... 4 
3. LIST OF TABLES ........................................................................................................................ 5 
4. ACKNOWLEDGEMENTS ........................................................................................................... 6 
5. ABSTRACT ................................................................................................................................ 7 
6. ZUSAMMENFASSUNG ............................................................................................................. 9 
7. INTRODUCTION ..................................................................................................................... 11 
7.1. Pancreatic cancer ............................................................................................................................ 11 
7.1.1. Epidemiology ................................................................................................................................... 11 
7.1.2. Etiology and risk factors .................................................................................................................. 11 
7.1.3. Diagnosis ......................................................................................................................................... 12 
7.1.4. Pathology ........................................................................................................................................ 13 
7.2. The tumor microenvironment ......................................................................................................... 13 
7.2.1. Role of the tumor microenvironment in cancer ............................................................................. 13 
7.2.2. The tumor microenvironment of PDAC ........................................................................................... 14 
7.2.3. The extracellular matrix (ECM)........................................................................................................ 15 
7.3. Pancreatic stellate cells (PSCs) ......................................................................................................... 16 
7.3.1. Activation of PSCs ............................................................................................................................ 16 
7.3.2. Interaction between PSC and PDAC ................................................................................................ 18 
7.4. Macrophages .................................................................................................................................. 19 
7.4.1. M1 macrophages (Classically activated) ......................................................................................... 19 
7.4.2. M2 macrophages (alternatively activated) ..................................................................................... 20 
7.4.3. Tumor associated macrophages (TAM)........................................................................................... 21 
7.4.4. Interaction between PSC and macrophages ................................................................................... 22 
7.5. The secretome ................................................................................................................................ 22 
7.5.1. Role of secretome in cancer ............................................................................................................ 23 
7.5.2. Role of secretome in biomarker identification ............................................................................... 24 
8. MATERIALS ............................................................................................................................ 25 
8.1. Cell lines and primary cells .............................................................................................................. 25 
8.2. Cell culture media and solutions ...................................................................................................... 26 
8.3. Chemicals, enzymes and general materials ...................................................................................... 26 
8.4. Lab equipment and disposables ....................................................................................................... 28 
8.5. Flow cytometry antibodies .............................................................................................................. 29 
8.6. ELISA and western blotting antibodies ............................................................................................. 29 
8.7. Kits ................................................................................................................................................. 30 
8.8. Primers ........................................................................................................................................... 30 
8.9. Buffers and Solutions ...................................................................................................................... 31 
9. METHODS .............................................................................................................................. 32 
9.1. Cell culture: ..................................................................................................................................... 32 
 2 
 
9.1.1. Regular cell maintenance ................................................................................................................ 32 
9.1.2. Collection of conditioned media and activation of PSCs ................................................................. 32 
9.1.3. Collection and handling of serum samples ..................................................................................... 33 
9.1.4. Monocyte isolation ......................................................................................................................... 34 
9.1.5. Monocyte differentiation to macrophages ..................................................................................... 35 
9.1.6. Treatment of macrophages with PSC and PDAC secretome ........................................................... 35 
9.2. Protein analysis with antibody microarray ....................................................................................... 36 
9.2.1. Antibody microarray production ..................................................................................................... 36 
9.2.2. Protein extraction ........................................................................................................................... 37 
9.2.3. Protein labeling ............................................................................................................................... 37 
9.2.4. Microarray incubation, scanning and image processing ................................................................. 37 
9.3. Flow Cytometry ............................................................................................................................... 38 
9.4. Immunoblotting .............................................................................................................................. 38 
9.5. RNA isolation .................................................................................................................................. 39 
9.6. cDNA synthesis and Real-Time PCR .................................................................................................. 39 
9.7. ELISA ............................................................................................................................................... 40 
9.8. Proliferation assay .......................................................................................................................... 40 
9.9. Nitric oxide (NO) production assay .................................................................................................. 40 
9.10. Reactive Oxygen Species (ROS) measurement ................................................................................. 41 
9.11. Arginase activity measurement ....................................................................................................... 41 
9.12. Statistical analysis ........................................................................................................................... 41 
10. RESULTS ................................................................................................................................ 43 
10.1. PSC activation, validation and secretome functional characterization .............................................. 43 
10.1.1. Activation of PSC with TNF-α .......................................................................................................... 44 
10.1.2. Characterization and validation of PSC secretome ......................................................................... 45 
10.1.3. Reactive oxygen species (ROS) measurement in the PSC ............................................................... 48 
10.1.4. Secretome of activated PSC increased cancer cell proliferation ..................................................... 49 
10.2. PSC and macrophage cellular interaction at the secretome level ...................................................... 51 
10.2.1. Differentiation of monocytes to macrophages ............................................................................... 52 
10.2.2. Analysis of macrophage polarization surface markers by flow cytometry ..................................... 54 
10.2.3. Analysis of cytokine and chemokines in macrophage at the RNA level .......................................... 56 
10.2.4. Arginase expression and NO production by the treated macrophages .......................................... 57 
10.2.5. ROS synthesis in macrophages up on treatment ............................................................................ 59 
10.2.6. Role of PSC-educated macrophages in PDAC cell proliferation ...................................................... 60 
10.3. Influence of IL-6 on macrophage polarization .................................................................................. 61 
10.3.1. Pre-polarization effect of IL-6 ......................................................................................................... 61 
10.3.2. Effect of IL-6 post-polarization ........................................................................................................ 62 
10.3.3. Expression profiling of macrophages treated with PSC secretome ................................................ 64 
10.4. Application of cancer cell secretome in diagnosis of pancreatic ductal adenocarcinoma ................... 69 
10.4.1. Secretome and array quality analysis ............................................................................................. 69 
10.4.2. Cancer cell secretome characterization and comparison ............................................................... 71 
10.4.3. Comparison of secretome to the related intracellular proteome ................................................... 73 
10.4.4. Protein variations in patient serum samples .................................................................................. 74 
10.4.5. Serum-based diagnostics ................................................................................................................ 77 
10.4.6. Validation by ELISA .......................................................................................................................... 80 
11. DISCUSSION .......................................................................................................................... 81 
 3 
 
11.1. PSC activation, validation and secretome characterization ............................................................... 81 
11.1.1. Activation of PSC with TNF-α .......................................................................................................... 81 
11.1.2. Characterization and validation of PSC secretome ......................................................................... 81 
11.1.3. The IPA analysis of the PSC’s secretome ......................................................................................... 82 
11.1.4. Increased ROS and PDAC proliferation by PSCs .............................................................................. 83 
11.2. Impact of PSCs secretome on monocyte differentiation and macrophages polarization .................... 84 
11.2.1. Monocyte differentiation to macrophages ..................................................................................... 84 
11.2.2. Macrophage polarization ................................................................................................................ 85 
11.2.3. Impact of IL-6 on macrophages pre and post-polarization ............................................................. 89 
11.2.4. Effect of IL-6 on arginase expression and NO synthesis .................................................................. 90 
11.2.5. Characterization of macrophages secretome and proteome ......................................................... 90 
11.3. Application of cancer cell secretome in PDAC diagnosis ................................................................... 91 
11.3.1. The array quality and cell secretome analysis ................................................................................ 92 
11.3.2. Cancer cell secretome characterization .......................................................................................... 92 
11.3.3. Comparison of cell secretome to the related intracellular proteome ............................................ 93 
11.3.4. Protein variations in patient serum samples .................................................................................. 93 
11.3.5. Serum-based diagnostics and validation ......................................................................................... 94 
12. CONCLUSIONS ....................................................................................................................... 95 
13. REFERENCES .......................................................................................................................... 97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
2. List of figures 
Figure 1. The tumor microenvironment of pancreatic ductal adenocarcinoma with the stromal cells.. 16 
Figure 2. Autocrine and paracrine factors mediating pancreatic stellate cell activation.. ....................... 17 
Figure 3. Workflow of PSC activation, collection of conditioned media of PDAC and fibroblast cell line 
and secretome extraction. ................................................................................................................ 34 
Figure 4. Workflow of macrophage incubation with the secretome of PSCs and PDAC ........................ 36 
Figure 5. The expression of FN-1 and α-SMA after activation of pancreatic stellate cells (PSC) with 
TNF-α.   ............................................................................................................................................... 44 
Figure 6. Effect of gemcitabine on PSC activation. ...................................................................................... 45 
Figure 7. Percentage and cellular location of the secreted proteins by activated PSCs ........................ 46 
Figure 8. Validation of secreted proteins by PSCs after stimulation with TNF-α. .................................... 47 
Figure 9. Reactive oxygen species (ROS) production by PSCs. ............................................................... 49 
Figure 10. Regulation of pancreatic ductal adenocarcinoma cell proliferation by the secretome of 
PSCs. .................................................................................................................................................. 50 
Figure 11. Box plots showing the proliferation of pancreatic ductal adenocarcinoma cells by IL-6. ..... 51 
Figure 12. Representative dot plot and FACS histogram show the purity of isolated CD14+ 
monocytes.. ........................................................................................................................................ 52 
Figure 13. Characterization of monocyte differentiation to macrophages. ............................................... 53 
Figure 14. Expression of HLA-DR on the surface of treated macrophages. ............................................ 53 
Figure 15. FACS histograms showing the expression of M1 (CD86) and M2 (CD163 and CD206) cell 
surface markers………………………………………………………………………………. 55 
Figure 16. Mean Fluorescence Intensity (MFI) of CD86, CD163 and CD206 markers expressed on 
macrophages.. ................................................................................................................................... 55 
Figure 17. Changes in cell surface marker expression and median fluorescence intensity (MFI) values 
of macrophage markers after treatment with the secretome of activated and non-activated 
PSC. .................................................................................................................................................... 56 
Figure 18. Real-time PCR analysis of macrophage cytokine and chemokine expression in primary 
macrophages treated with PSCs secretome.   .............................................................................. 57 
Figure 19. Effect of the PSCs secretome on arginase activity and expression by macrophages. ........ 58 
Figure 20. Nitric oxide (NO) production by macrophages and PSCs. ....................................................... 59 
Figure 21. Reactive oxygen species (ROS) production by macrophages.. .............................................. 60 
Figure 22. Regulation of pancreatic ductal adenocarcinoma cell (Panc-1) proliferation by the 
secretome of pre-treated macrophages with the PSCs secretome.   ........................................ 61 
Figure 23. Effect of IL-6 in stimulating macrophage’s surface marker expression. ................................. 62 
Figure 24. Effect of IL-6 on the expression of macrophage’s surface markers after polarization. ........ 63 
Figure 25. Influence of IL-6 on arginase activity and nitric oxide synthesis in macrophages.. .............. 64 
Figure 26. Effect of PSC secretome on macrophage (THP-1) secretome profile and function. ............ 66 
 5 
 
Figure 27. Ingenuity Pathway Analysis for the effects of PSC secretome on THP-1 macrophages at 
the proteome level.  . ........................................................................................................................ 68 
Figure 28. Molecules in the macrophages affecting the invasion of tumor cells...................................... 68 
Figure 29. Quality assessment of microarray analyses. .............................................................................. 71 
Figure 30. Proteins that are commonly regulated in secretome and intracellular proteome of the tumor 
cells. ..................................................................................................................................................... 74 
Figure 31. AUC values of the 189 individual serum markers...................................................................... 76 
Figure 32. Proteins that were similarly regulated in both tumor cell secretome and PDAC patient sera..
 ............................................................................................................................................................. 77 
Figure 33. Diagnostic potential of the protein signatures in serum. ........................................................... 78 
Figure 34. Diagnostic potential of PDAC and CP serum markers only. .................................................... 79 
Figure 35. Discrimination of sera from PDAC and CP patients. ................................................................. 79 
Figure 36. ELISA validation of identified marker proteins. .......................................................................... 80 
 
 
 
3. List of Tables 
Table 1. Downstream effects analysis of activated PSC secretome. ......................................................... 47 
Table 2. Functional annotation of some molecules upregulated by the TNF-α stimulation based on 
ingenuity pathway analysis (IPA).  . ................................................................................................. 48 
Table 3. Predicted functional effect of activated PSC secretome on cell death and proliferation.. ....... 48 
Table 4. Downstream effect analysis for the secretome expression profiling data of macrophages after 
treatment with PSC secretome.. ..................................................................................................... 65 
Table 5. Downstream effect analysis for the proteome expression profiling data of macrophages after 
treatment with PSC secretome. ....................................................................................................... 67 
Table 6. Characteristic and clinical features of cell lines used in secretome collection. ......................... 70 
Table 7. List of the most frequently predicted functions associated with the secretome of pancreatic 
cancer cell lines. ................................................................................................................................ 73 
Table 8. Characteristics of healthy donors and patients from whom serum samples were collected. .. 75 
 
 
 
 
 
 
Acknowledgments 
6 
 
4. Acknowledgements 
I would like to thank my supervisor Dr. Jörg Hoheisel for giving me the chance to 
work in his group. My deepest appreciation goes to him. I’m sure, without his 
constructive comments, support, guidance and persistent help this thesis would not 
have been possible. Thanks for the wonderful atmosphere in the group and for the 
social communication.  
I have greatly benefited from working with Dr. Alhamdani, therefore, I would like to 
express my gratitude. Thanks for the team work and the discussions. 
I appreciate the feedback offered by the members of my thesis advisory committee, 
Prof. Dr. Gert Fricker and Prof. Dr. Aurelio Teleman. Thanks for the helpful 
suggestions, concerns and advices. 
I’m deeply grateful to all the members of the B070 group. I can’t find any words to tell 
you for creating the nice atmosphere, the Pasta club, the football and tennis playing, 
for the excursions, parties….so on.  
Big thanks go for Janek, my roommate who brought me mineral water and Steffie for 
her continuous help. Laureen made enormous contribution to the big experiments, 
I’m really grateful for that. I also want to thank Patrick for his nice discussions.  
I would like to thank Andrea, Sandra and Melanie for their support and help. I will not 
forget our discussions with Soroosh. I appreciate the efforts and helps of the master 
and bachelor students for their generous support, Kyra, Justus, Maureen, Hannah, 
Benedict, Jan 
To my parents, my brothers and friends who have supported me from the beginning 
till the end through this long journey. You are the ones I share this achievement with. 
I received invaluable support and love from my wife. Her persistent motivation and 
encouragement made me do my best. 
Finally, I would also like to express my gratitude to the HCDP and DAAD for their 
financial support. 
 
  
Abstract 
7 
 
5. Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy remaining 
incurable to date. The tumor cells and the relevant oncogenic signaling have been 
extensively investigated, still, the exact molecular and cellular pathology of the 
disease is not well known due to its fibrous stroma. The tumor microenvironment of 
PDAC is characterized by a dense desmoplastic stroma consisting of fibroblast, 
pancreatic stellate cells (PSC), immune cells and the extracellular matrix 
components. PSCs and tumor associated macrophages (TAM) are the most 
abundant and important cells in the tumor microenvironment of PDAC and their 
cellular communication play a significant role in PDAC progression and immune 
escape. 
The molecular mechanisms of PSCs activation and the role of their secreted proteins 
in macrophage polarization as well as the possibility of defining biomarkers from the 
secretome of pancreatic cancer cells were studied in this thesis. The secretome of 
tumor necrosis factor-alpha (TNF-α) activated PSCs were analyzed and validated 
using different techniques. Activation of PSCs resulted in regulating the secretome 
profile of PSCs and increased ROS production. The study also demonstrated that 
activated PSCs secrete numerous proteins which are associated with the cancer cell 
proliferation and immune cells activation.  
Co-culturing PDAC cells with the secretome of activated PSCs resulted in a 
significant increase of cells proliferation. Moreover, the secretome of PDAC cells and 
activated PSCs promoted the expression of HLA-DR on monocytes and induced the 
polarization of macrophages into the immunosuppressive M2 phenotype. The M2 
polarization was confirmed by their ability to express CD163 and CD206 surface 
markers, higher arginase activity and interestingly, their conditioned medium 
increased Panc-1 cell proliferation. Additionally, interleukin-6 (IL-6) differentially 
regulated the expression of M1 and M2 surface markers pre- and post-polarization.  
Moreover, the secreted molecules by pancreatic cancer cells, sera of PDAC patients, 
chronic pancreatitis (CP) and sera from healthy donors were studied for the 
establishment of a set of defined biomarkers. The study indicated that eight markers 
which were similarly regulated in the PDAC cell secretome and serum of PDAC 
patients could increase the accuracy of PDAC diagnosis up to 10%.  
Abstract 
8 
 
Taken together, these results will provide insight into the complex and dynamic 
microenvironment of pancreatic cancer and show the critical role of tumor and 
stromal cell’s secretome in PDAC development and cellular communications in the 
tumor microenvironment. 
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6. Zusammenfassung 
Das duktale Pankreasadenokarzinom (PDAC) ist eine höchst letale maligne 
Erkrankung, die bis heute als unheilbar gilt. Die Tumorzellen und die relevanten 
onkogenen Signalwege wurden umfassend untersucht, dennoch ist die genaue 
molekulare und zelluläre Pathologie der Erkrankung auf Grund des fibrösen Stromas 
bisher nicht ausreichend bekannt. Die Tumormikroumgebung von PDAC ist durch ein 
dichtes desmoplastisches Stroma bestehend aus Fibroblasten, Sternzellen des 
Pankreas (PSC), Immunzellen sowie Komponenten der extrazellulären Matrix 
gekennzeichnet. PSC und Tumor-assoziierte Makrophagen (TAM) sind die am 
häufigsten vorkommenden und wichtigsten Zellen in der Tumormikroumgebung von 
PDAC und ihre zelluläre Kommunikation spielt eine bedeutende Rolle für die 
Tumorprogression und die Fähigkeit der Tumorzellen, den Kontrollmechanismen des 
Immunsystems zu entgehen („immune escape“).     
In dieser Arbeit wurden die molekularen Mechanismen  der PSC-Aktivierung, der 
Einfluss der von PSC sezernierten Proteine auf die Makrophagen-Polarisation sowie 
die Möglichkeit, basierend auf dem Sekretom der Pankreaskrebszellen Biomarker zu 
definieren, untersucht. Das Sekretom von TNF-α-aktivierten PSC wurde mittels 
verschiedener Techniken analysiert und validiert. Die Aktivierung resultierte in einer 
Regulierung des Sekretomprofils der PSC und einer vermehrten Produktion von 
ROS. The Untersuchung zeigte außerdem, dass aktivierte PSC zahlreiche Proteine 
sezernieren, die mit der Proliferation von Krebszellen und der Aktivierung von 
Immunzellen assoziiert sind.  
Die Co-Kultivierung von PDAC-Zellen mit dem Sekretom aktivierter PSC führte zu 
einer signifikanten Steigerung der Zellproliferation. Darüber hinaus förderten sowohl 
das Sekretom von PDAC-Zellen als auch das Sekretom von aktivierten PSC die 
Expression von HLA-DR auf Monozyten und induzierten eine Polarisierung von 
Makrophagen in den immunsuppressiven M2-Phenotyp. Die M2-Polarisation der 
Makrophagen wurde durch ihre Fähigkeit die Oberflächenmarker CD163 und CD206 
zu exprimieren, eine höhere Arginaseaktivität und, interessanterweise, die Tatsache, 
dass ihr konditioniertes Medium die Proliferation von Panc-1-Zellen erhöhte, 
festgestellt. Außerdem wurde die Expression von M1- und M2-Oberflächenmarkern 
sowohl vor als auch nach der Polarisation durch Interleukin-6 (IL-6) differentiell 
reguliert.    
Zusammenfassung 
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Des Weiteren wurden die von Pankreaskrebszellen sezernierten Moleküle sowie 
Seren von PDAC-Patienten, Patienten mit chronischer Pankreatitis (CP) und 
gesunden Spendern mit dem Ziel untersucht, eine Reihe von definierten Biomarkern 
festzulegen. Die Analyse ergab, dass acht Marker, welche in dem Sekretom von 
PDAC-Zellen und dem Serum von PDAC-Patienten in gleicher Weise reguliert waren, 
die Genauigkeit einer PDAC-Diagnose um bis zu 10% erhöhen konnten. Insgesamt 
werden diese Ergebnisse einen Einblick in die komplexe und dynamische 
Mikroumgebung des Pankreaskrebs geben sowie die entscheidende Rolle des 
Sekretoms von Tumor- und Stromazellen in der Entwicklung von PDAC und der 
Zellkommunikation in der Tumormikroumgebung zeigen.     
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7. Introduction 
7.1. Pancreatic cancer  
7.1.1. Epidemiology 
Pancreatic cancer is a highly lethal malignancy with near 100% mortality and a 
dismal prognosis. Pancreatic ductal adenocarcinoma (PDAC) is the most aggressive 
and common type of pancreatic cancer which accounts for around 95% of cases [2]. 
The 5-year survival rate of PDAC is recently increased to about 8% still, it is ranked 
as the fourth leading cause of cancer deaths among the most common cancers in the 
world [3, 4]. It is assumed that the mortality of PDAC is equal to its incidence and the 
average survival period after diagnosis is around five months. Pancreatic cancer 
causes more than 331000 deaths in 2012 and the highest incidence and mortality 
rates are found in males in the developed countries [5]. The ratio is increasing, in 
2015 for example, an estimated 367000 new cases of pancreatic cancer were 
diagnosed worldwide of which 359,000 were died in the same year [6].Therefore, 
pancreatic cancer is expected to become the second leading causes of cancer death 
by 2030 [7]. This is in part due to the fact that most patients are diagnosed only at the 
advanced stages with already metastatic so that only 20% of the patients are eligible 
for tumor resection [6]. The high mortality rate can also be attributed to the absence 
of apparent signs and symptoms during early stages, a lack of sensitive and specific 
tumor markers as well as inadequate therapeutic agents [8]. Finally, pancreatic 
cancer exhibits a very early and high rate of metastases to liver, peritoneum and lung 
which are the most common causes of cancer death [6, 9]. 
7.1.2. Etiology and risk factors 
Although PDAC is the most intensively investigated type of pancreatic cancer, still it’s 
molecular causes are not well understood [2]. The activation of oncogenes and 
inactivation of the tumor suppressor genes by mutations are the main genetic 
alteration in PDAC [10]. In a global genome analysis of human pancreas the most 
common signaling pathways such as, metabolism, cell cycle, cellular repair 
mechanism and metastasis were discovered which are affected in the genome of 
more than 75% of pancreatic cancer cases [11]. However, genetic factors comprise 
only 10% of all pancreatic cancer cases and the rest 90% is attributed to the 
environmental risk factors [12]. The most strongly associated risk factors to PDAC is 
family history, chronic pancreatitis (CP), smoking, diabetes, alcohol consumption, 
age and obesity. Smoking, for example, increases the risk by 75% compared to the 
Introduction 
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non-smokers and the risk remains even after 10 years of quitting  [13, 14]. Further 
risk factors are age, still, pancreatic cancer rarely occurs before the age of 40 
whereas over 80% of cases develop between the 60 and 80 years [15]. Studies have 
also shown that individuals with diabetes showed a twofold  increased occurrence of 
pancreatic cancer [16] however, the risk is decreased with the duration of diabetes 
[17]. Pancreatic cancer has been associated with numerous risk factors such as life 
style, diet, infections and medical conditions all of which are well reviewed [14, 18, 
19]. The studies have classified the risk factors to the high-risk groups, moderate risk 
and low risk, even factors which are not associated to PDAC are included [14]. 
Nevertheless, there is very few risk factors with relative risks greater than two which 
might be valuable for screening. 
7.1.3. Diagnosis 
Pancreatic cancer develops insidiously as the early indications are non-specific and 
can be easily missed due to the lack of reliable and sensitive diagnostic markers [20]. 
The available serum biomarkers, such as carcinoembryonic antigen (CEA) and 
carbohydrate antigen 19-9 (CA19-9), are of only limited utility due to a significant lack 
of specificity and sensitivity [21, 22].  It has been shown that around 10% of PDAC 
patients do not express the enzyme needed for CA19-9 synthesis, therefore they are 
not able to produce CA19-9. Besides,  patients with small cancers show false 
negative [23] whereas false positive CA19-9 is also frequently observed in patients 
with CP, hepatocellular cancer, upper gastrointestinal tract and ovarian cancer [24]. 
Due to these limitations and inabilities of CA19-9, studies presented several other 
markers such as MIC1[25],  AFP [26], SPan-1 [27] and PAM4 [28], however, only 
PAM4 achieved the required sensitivity and specificity in diagnostics. PAM4 is the 
monoclonal antibody which is highly specific for a glycoprotein MUC1 produced by 
pancreatic cancer. It is identified in more than 90% of pancreatic cases whereas in 
normal pancreas it was not detected [28, 29]. PAM4 presented a high sensitivity and 
specificity of 77% and 95% respectively, thereby it is recommended as a potential 
biomarker for early detection of PDAC [29]. Moreover, there are some genetic and 
epigenetic markers and microRNA markers still, they failed to be successfully 
implemented in PDAC detection [30]. “Therefore, the search is on for better 
performing biomarkers in body fluids that could be applied effectively in a non-
invasive and routine manner for a timely detection of the disease. Recently, GPC1+ 
circulating exosomes were described as highly accurately detecting pancreatic 
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cancer patients [31]. With respect to protein profiles, the screening of PDAC patient 
sera for suitable biomarkers was recently reported using recombinant single-chain 
variable fragment (scFv) binders that target 57 mainly immunoregulatory 
biomolecules [32]. However, the definition of specific protein biomarkers in blood or 
other body fluids can be a challenge. One reason is the fact that the origin of the 
proteins are quite variable [33, 34]” 
7.1.4. Pathology 
Most of the pancreatic cancers are originating from exocrine pancreas. PDAC is the 
most common form of pancreatic cancer and accounts for around 95% of all 
pancreatic cancers [6]. The origin of PDAC is not known yet, however, it is postulated 
that PDAC originated from ductal cells of the exocrine pancreas [35]. Moreover, it 
has been reported that PDAC develops from the precursor lesions, pancreatic 
intraepithelial neoplasia (PanIN), intraductal mucinous papillary neoplasm (IMPNs) 
and mucinous cystic neoplasms (MCNs) [36]. PanIN is the most common precursor 
lesion of PDAC which is characterized by the acinar to ductal metaplasia (ADM), a 
key event for PDAC [37, 38]. Chronic pancreatitis is thought to promote PanIN via 
inducing ADM and leading to the PDAC development [39, 40]. The first change in 
PanINs is KRAS mutation which leads to the increased STAT, MAPK and AKT/PI3K 
signaling pathways [41, 42]. Of note, KRAS mutation is the most common and 
outstanding hallmark of PDAC which is found in more than 90% of PDAC patients 
[43]. Constitutive mutation of KRAS leads to the upregulation of oncogenic proteins 
such as cMYC and EGFR as well as subsequent changes in tumor suppressor 
genes, such as p21 and p53, which are associated to the epithelial transformation 
into carcinoma [44]. The American Joint Committee on Cancer (AJCC) and the 
International Union for Cancer Control (UICC) have released TNM staging system to 
characterize tumor stages. The system determines the stage of the disease by the 
size of the primary tumor and its relationship to the celiac axis (T), the presence or 
absence of regional lymph node involvement (N), and distant metastases (M) and 
provides a “stage grouping” based on T, N, and M [45]. 
7.2. The tumor microenvironment 
7.2.1. Role of the tumor microenvironment in cancer  
Tumors are not anymore considered only a homogeneous accumulation of malignant 
cells but rather a complex ecosystem made of tumor cells and the recruited non-
Introduction 
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tumor cells. The interactions between these cells creates the tumor 
microenvironment (TME) or stroma [46]. The TME consists of different stromal cells 
along with the extra cellular matrix and soluble molecules. Due to the direct or 
indirect interactions of stromal cells with the tumor cells, they are transformed to an 
aberrant phenotype and play a critical role in tumorigenesis [47, 48]. These 
communications are primarily driven by the altered cytokines, chemokines and 
growth factors which were released into the extracellular space by the stromal cells 
[46, 49]. The direct stimulations contribute to hypoxia, increased cell proliferation and 
gene expression and by this means contribute to the acquirement of caner hallmarks 
[46, 48]. 
7.2.2. The tumor microenvironment of PDAC 
Along with the oncogenic mutations, histologically, PDAC is characterized by a 
desmoplastic tumor microenvironment (TME) which comprises up to 90% of the 
tumor mass [50, 51]. The TME of PDAC plays a key role in tumor initiation, 
progression, metastasis, and response to treatment. For instance, the desmoplastic 
reaction is creating a high intratumoral pressure and solid stress leading to the 
vasculature collapse [52]. This consequently affects the access of oxygen and 
nutrients between the smaller compartments within tumors, causing hypoxia which 
plays an active role in promoting tumor progression, malignancy, and resistance to 
therapy [53].The TME of PDAC is not a static entity and comprised of pancreatic 
stellate cells (PSC) [54], fibroblast [55], immune cells [56], endothelial cells and the 
extra cellular matrix (ECM) components [57]. It has been shown that, the fibrotic 
matrix functions as a physical barrier generating stiffness, insolubility, spatial 
arrangement and porosity, thereby creating unique mechanical support and is giving 
elasticity to the tissue [58, 59]. However, studies found that this structural platform is 
the pool of secreted cytokine and growth factors which initiate carcinogenesis [60, 
61]. In addition, the stromal cells in the TME promote tumor growth and proliferation 
and modify the ECM as such, they increase metastasis [62, 63]. So far, the specific 
interactions among stromal cells as well as the underlying molecular mechanisms are 
only partially known. Studies demonstrated that, the overexpression of several 
growth factors, such as, Vascular endothelial growth factor (VEGF), epidermal growth 
factor (EGF) and fibroblast growth factor (FGF) with their receptors are the result of 
the high proportion of stromal cells in PDAC [64]. Understanding the cellular 
constituents of TME and how the stromal cells interact with each other, leading to the 
Introduction 
15 
 
tumor growth, is therefore necessary to improve PDAC therapy and increase survival 
rate [57]. 
7.2.3. The extracellular matrix (ECM) 
The ECM is the non-cellular components of the tissue which is composed of a 
complex network of several proteins secreted into the extracellular space. In normal 
tissues, the ECM keeps the integrity of the tissue by providing physical supports to 
the cells and it is also the source of crucial biochemical reactions maintaining tissue 
hemostasis [59]. Another important function of the ECM is to protect cells by a 
buffering action to maintain the water retention [65]. However, the ECM undergoes 
constant remodeling by the enzymes like matrix metalloproteases (MMPs) and tissue 
inhibitor metalloproteinases (TIMPs), an important function associated with wound 
healing [66]. The excessive and uncontrolled ECM remodeling is therefore increasing 
the tissue stiffness which is characteristics of solid tumors. It has already been found 
that the stiffening of the ECM in pancreatic cancer reduces the efficacy of 
chemotherapeutic agents and directed the cancer cells to gain tumorigenic potential 
[67]. Changes in the ECM can also influence pancreatic cancer invasion. For 
instance, expression of fibroblast activation protein (FAP-α) was shown to change the 
orientation of fibronectin fibers leading to increased scattering and motility of 
pancreatic cancer cells [68]. The tumor and stromal cells in pancreatic cancer, secret 
different components such as collagens, glycoproteins, growth factors and 
proteoglycans as well as modulators of the matrix such as, periostin, tenascin C, 
thrombospondin and secreted protein acidic and rich in cysteine (SPARC) [69]. 
SPARC is a noncellular remodeling element of the ECM which enhances intratumoral 
drug delivery [70]. Studies have shown that, periostin and tenascin-C are contributed 
to the enhanced tumor proliferation, aggressiveness and migration whereas 
osteopontin associated with a better survival rate [69]. Nevertheless, the stromal cells 
in PDAC are numerous and they have a key role in ECM degradation and tumor 
development. PSCs, CAFs and TAMs are the main contributors in such desmoplastic 
changes as they have been identified as the main source of proteins and are 
attributed to the deposition of the ECM [71-73] as in Error! Not a valid bookmark 
self-reference.. 
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7.3. Pancreatic stellate cells (PSCs) 
In the healthy pancreas, quiescent PSCs are located in the periacinar space in close 
proximity to the basolateral aspect of acinar cells.  PSCs comprise around 7% of the 
total pancreatic cells and are characterized by expression of desmin, vimentin, nestin 
and glial fibrillary acidic protein (GFAP) [74]. A very typical feature of quiescent PSC 
is the existence of vitamin-A containing lipid droplets which is one of the 
differentiating markers of PSCs from fibroblasts [75]. The main functions of PSCs in 
normal pancreas are maintaining the structure of the basement membrane, growth of 
the ECM and production of MMPs and TIMPs for tissue homeostasis [76, 77].  
7.3.1. Activation of PSCs 
During pancreatic injury and chronic pancreatitis (CP), PSCs transform into activated 
myofibroblast-like cells which express alpha-smooth muscle actin (α-SMA) filaments 
and produce ECM components such as collagen and fibronectin [74]. PSCs are 
activated by different inflammatory factors, cytokines and growth factors such as 
transforming growth factor beta-1 (TGF-β1), fibroblast growth factor (FGF-2), tumor 
necrosis factor alpha (TNF-α), IL-1, activin A, IL-6, IL-8, platelet-derived growth factor 
(PDGF) and vascular endothelia growth factor (VEGF) [71, 78]. These factors are 
produced by the different cells in the TME such as macrophages, acinar cells and 
platelets as well as by the pancreatic cancer cells. Moreover, reactive oxygen 
Figure 1. The tumor microenvironment of pancreatic ductal adenocarcinoma with the stromal 
cells. Activation of pancreatic stellate cells and recruitment of different immune cells to the tumor site 
changes the basement membrane consequently leading to fibrosis.  
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species (ROS), ethanol and pressure are also known to activate PSCs [79, 80]. In 
normal conditions, activated PSCs undergo apoptosis after wound healing [81] 
however, repeated injury and recurrent inflammation keep the PSCs activated, 
leading to produce excessive amount of ECM proteins and causing fibrosis in PDAC 
[82]. As it is shown in the Figure 2, the persistent activation of PSCs is in part due an 
autocrine loop created by the secretion of growth factors by their own [1, 82].   
 
Figure 2. Autocrine and paracrine factors mediating pancreatic stellate cell activation. 
Cytokines and growth factors secreted by injured acinar cells, immune cells and cancer cells activate 
the pancreatic stellate cells (PSCs) in a paracrine fashion and stimulate them to secrete various 
factors. These factors secreted by PSCs in turn acts in a paracrine fashion and sustains its activation. 
This autocrine and paracrine signal cycles may help PSCs to retain its activated phenotype, resulting 
in excess ECM deposition, culminating to pancreatic fibrosis. Illustration by the author. Bynigeri et al. 
2017 [1],with permission. 
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7.3.2. Interaction between PSC and PDAC  
Studies have shown that the increased tumor growth of pancreatic cancer is due to 
the presence of important interactions between PSCs and tumor cells [78, 83]. In this 
reciprocal interaction, pancreatic cancer cells recruit PSCs, for example, by secreting 
sonic hedgehog (SHH) protein, and in turn, overexpression of MMP3, MMP13 and 
MMP14 by PSCs promote the proliferation and invasion of PDAC cells [84, 85]. It has 
been shown that conditioned medium of PSCs increases the proliferation of 
pancreatic cancer cells via stimulating the expression of galectin-3 [86]. Decreased 
occurrence of apoptosis is found in PSC rich tumors. In agreement with that, the 
conditioned medium of PSCs is proven to reduce the apoptotic effect of oxidative 
stress on pancreatic cancer cells [83]. The anti-apoptotic effect of PSCs could be 
attributed to the secretion of ECM proteins, fibronectin and laminin, which are shown 
to inhibit both mitochondrial dysfunction and caspase activity [87].  
Recently, it was shown that the secreted IL-6 by activated PSCs induced PDAC cell 
invasion and colony formation through activating STAT-3 signaling [88]. Of note, the 
activation of notch signaling pathway in direct co-culture of PSCs with PDAC cells is 
already connected with the proliferation of PDAC cells [89]. Moreover, compelling 
evidences have proven the crucial contribution of activated PSCs in stimulating 
PDAC invasion, migration and metastasis via secreting PDGF, TGF-β, FGF2, EGF, 
connective tissue growth factor (CTGF), MMPs, adrenomedullin (AM) stroma cell-
derived factor-1 (SDF-1), and galectin-1 proteins [90-93]. Interestingly, 
immunohistochemical analysis of PDAC tissues, showed that the number of PSCs 
which express CD10 surface marker are remarkably higher in pancreatic tumor than 
in normal tissue [85]. 
Nevertheless, the interaction between PSCs and PDAC cells are not restricted to 
only the paracrine signaling. For instance, by injecting PSCs with pancreatic cancer 
cells in mice, Xu et al. revealed the physical interaction between PSCs and tumor 
cells. They found that, the PSCs which accompanied cancer cells to the metastatic 
sites, stimulate angiogenesis and are able to intravasate or extravasate to and from 
blood vessels [94].  
There are several investigations ongoing to unravel the mechanism of 
chemoresistance in PDAC. Hypoxia is described to affect chemotherapy via different 
signaling pathways such as NF-B, hedgehog pathway, ERK1/2 signaling and 
reduction of produced ROS [95-97]. It has been previously found that PSCs are 
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activated in hypoxia [98] and also contribute to the hypoxic microenvironment of 
PDAC [60]. However, PSCs can also regulate tumor vasculature and hypoxia by 
secreting pro-angiogenic factors such as FGF and VEGF [99, 100]. The role of 
activated PSCs in PDAC chemoresistance could be due to the physical barrier for 
drug delivery or through secreting different proteins. Wang et al. have demonstrated 
that gemcitabine and radiotherapy were less effective in cancer cells treated with the 
conditioned medium of PSCs [101]. The resistance could be mediated by the 
secretion of cysteine-rich angiogenic inducer 61 (CYR61) by the activated PSCs 
which reduces the expression of nucleoside transporters hENT1 and hCNT3 [102]. 
Additionally, the expression of cytidine deaminase (CDA) in PSCs may also 
deactivate gemcitabine, reducing its effect and thus protecting tumor cells [103]. In 
another study by Zhang et al. indicated that PSCs promote resistance to gemcitabine 
through activating FAK-AKT and ERK1/2 signaling pathways through paracrine SDF-
1α/CXCR4 signaling and, subsequently, the IL-6 autocrine loop in pancreatic cancer 
cells. Furthermore, release of NO, periostin and IL-1β by PSCs is attributed to the 
chemoresistance [90, 104]. 
7.4. Macrophages 
The innate and adaptive immune responses are the two main immune reactions of 
human immune system. Macrophages are differentiated from monocytes of the bone 
marrow and are the most important cell types of the innate immune system. They 
destroy pathogens and phagocytose cell debris, facilitate tissue remodeling during 
wound healing, orchestrate inflammation and stimulate adaptive immunity [105]. 
Macrophages are originally heterogenous; tissue macrophages are originating from 
the yolk sac progenitors while those involved in pathogen clearance arise from bone 
marrow [105, 106]. It is known that monocytes are attracted by chemoattractant 
signals to migrate to the tissues in which they differentiate into macrophages [106].  
7.4.1. M1 macrophages (Classically activated) 
Activated macrophages are divided into two functional phenotypes based on their 
response to the environmental signals. The M1 or classically activated macrophages 
are triggered by bacterial lipopolysaccharide (LPS), IFN or TNF-α [107]. They are 
proinflammatory macrophages which are able coordinate an effective adaptive 
immune response against tumors and intracellular pathogens [108]. M1 
macrophages secret high amounts of inflammatory cytokines such as TNF-α, IL-1β, 
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IL-12, IL-23, IL-6, ROS [109, 110] and show a highly active iNOS enzyme which 
produces nitric oxide (NO) [111]. M1 macrophages express CD80 (B7-1) and CD86 
(B7-2) on their surface which are significant to initiate immune response and activate 
T-cells [112]. CD80/86 are critical ligands for T-cell costimulatory molecule CD28 and 
are one of the highly expressed markers on M1 macrophages, CD86 is also 
expressed but at a very low ratio in M2a subtype [113, 114]. High NO production is 
the main weapon of M1 macrophages against pathogens and tumors. NO is a small 
lipophilic molecule that can easily cross membranes and reacts chemically with ROS 
molecules, such as superoxide, to generate biologically active derivatives [115]. In 
tumors, depending on its concentration, NO has both pro- and anti-tumor effects 
[116]. 
7.4.2. M2 macrophages (alternatively activated) 
On the contrary, M2 macrophages are activated by anti-inflammatory factors such as 
IL-4, IL-10, IL-13 and glucocorticoid hormones [117]. M2 macrophages mediate 
immunosuppression by secreting IL-10 and TGF-β and play a critical role in wound 
healing [110, 118]. In respond to the activating stimuli, M2 macrophages are divided 
into different subtypes which are M2a, M2b and M2c [111]. M2 macrophages are 
characterized by the cell surface expression of the macrophage mannose receptor 
(MMR) CD206 [119], scavenger receptor CD163 [118] and the synthesis of soluble 
factors, such as the CC chemokine ligand 17 (CCL17) , IL-10  [120], CCL-18 and 
TGF-β [121]. Beside the surface markers and cytokines, M2 macrophages induce 
arginase enzyme which metabolizes arginine and produces proline [110, 118]. To 
distinguish between the two activation states of macrophages, metabolism of L-
arginine is thought to be a distinctive means [122]. Arginase-1 (Arg-1) is a key 
feature of M2 macrophages which contributes in wound healing and fibrosis by 
catalyzing arginine to urea and ornithine [122, 123]. Of note, ornithine is the 
precursor of polyamines which are critical for collagen synthesis and cell proliferation 
[124]. It is already known that, Arg-1 is induced by exogenous Th2 cytokines such as 
IL-4 and IL-13 through STAT-6 activation [125, 126].  
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7.4.3. Tumor associated macrophages (TAM) 
Macrophages that migrate to the tumor environment are called tumor associated 
macrophages (TAM) which are associated with poor prognosis in pancreatic cancer 
[127, 128]. TAMs have a key role in tumor initiation, development and metastasis 
[109]. TAMs are M2-resembling macrophages which are activated by factors such as 
IL-4, IL-10, IL-13, colony stimulating factor-1 (CSF-1) and TGF-β [129]. However, 
their phenotype varies during the stages of tumor development and often reflects a 
mix of M1 and M2 [130].   
M1 and M2 macrophages differ functionally; M1 macrophages are dominated in 
acute pancreatitis whereas M2 macrophages are dominant in chronic pancreatitis 
and in PDAC which are associated with poor prognosis [129]. It is assumed that the 
persistent release of cytotoxic molecules by M1 macrophages destroy infectious 
agents and resolve inflammation however, secreted pro-inflammatory factors may 
stimulate cancer cells survival [112, 131]. It has been shown that CCL2 and IL-6 in 
the TME attract monocytes and eventually polarize them into M2 type [132]. 
Moreover, recruitment and polarization of macrophage can also be initiated by the 
ECM components such as hyaluronic acid [133] or by hypoxia [134]. TAMs could 
have different functions in the TME. It has been demonstrated that TAMs inhibit anti-
tumor immune response mediated by T cells followed by the promotion of tumor 
progression [135]. Interestingly, high numbers of TAMs are exist in the hypoxic area 
of the tumor where they increase VEGF expression leading to the recruitment of 
monocytes and induce M2 polarization via IL4 [136, 137]. It has been found that 
TAMs are able to enhance anti-cancer drug resistance of cancer stem cells in 
cooperation with IL-6 [138].  
Previous studies have indicated that IL-6 which is also secreted by PSCs [88], is 
considered as the main regulator of immunosuppression in autoimmune diseases 
and cancer [139]. IL-6 induced the expression of IL-4 receptor on macrophages 
which activates signal transducer and activator of transcription-6 (STAT-6) after IL-4 
binding. STAT-6/IL-4 axis is then promoting M2 phenotype of macrophages [140] 
which in turn induce the production of high amount of arginase-1 [141]. Moreover, the 
immunosuppression could be partly due to the expression of ligands for the inhibitor 
receptors PD-1 (programmed cell death protein 1) and cytotoxic T-Lymphocyte 
Antigen-4 (CTLA-4) [142]. Granulocyte colony-stimulating factor (G-CSF), for 
example, increases CD163 expression and prevents cell apoptosis [143]. Of note, G-
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CSF is highly upregulated in the conditioned medium of BxPC-3, a highly metastatic 
human pancreatic cancer cell line, and is responsible for the suppression of dendritic 
cells in the pancreatic cancer [144].  
7.4.4. Interaction between PSC and macrophages 
Several investigations have been done to understand the role of stroma in immune 
escape mechanism of PDAC cells, still, the available therapies are inadequate [145]. 
This however, is due to the fibrous microenvironment of PDAC in which the stromal 
and cancer cells creating a barrier for immune- and chemotherapeutic agents [146]. 
As mentioned above, the interaction between PDAC and PSCs have been 
tremendously studied and the activated signaling pathways were elucidated [147, 
148].  Moreover, the immune cells communication with the tumor cells in the stroma 
of PDAC has revealed the contribution of tumor cells in regulating immune response 
[73, 149]. Nonetheless, the cellular cross-talks between PSCs and macrophages are 
limited. It has been shown that macrophages are recruited to the tumor area by M-
CSF and CCL-2 pathways where they gain the anti-inflammatory phenotype [150, 
151]. Therefore, determining the tumor-promoting impact of macrophages represents 
a promising target [152]. For instance, Affara et al. showed that depletion of B-cells 
resulted in reprogramming the macrophages which leads to the inhibition of tumor 
[153].  
Macrophages can communicate with the PSC by which they increase the cytokine 
production. In a study by Shi et al., the co-cultured quiescent PSCs with 
macrophages became activated and produced high amount of IL-6, MCP-1 and 
KC/CXCL1. This interaction dramatically increased G-CSF/CSF3, MCP-1, MIP-
1α/CCL3, MIP-1β/CCL4, MIP-2/CXCL2 and TNF in macrophages resulted in 
fibrogenesis [154]. Similarly, secretion of granulin by metastasis associated 
macrophages resulted in activating hepatic stellate cells and induced periostin 
production which resulted in sustaining metastatic tumor growth [155]. Collectively, 
understanding the molecular interactions among stromal cells and tumor cells in the 
tumor microenvironment can be considered as a target for therapy. 
7.5. The secretome 
The term secretome was first introduced by Tjalsma et al. and later revised by 
Agrawal et al. which stands for all proteins that are released from cells into the 
extracellular space [156, 157]. In the conventional protein secretion pathway, 
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secreted proteins contain N-terminal signal peptides which guides them to the 
endoplasmic reticulum (ER) then to the Golgi apparatus which subsequently fused 
with the plasma membrane and released them into the microenvironment [158]. 
However, the unconventional pathway includes Golgi-independent trafficking of 
integral membrane proteins [159]. Of any kind  the pathways are, about 10% of the 
22,000 protein-encoding human genes are estimated to encode proteins that are 
secreted which accounts for 13-20% of total human proteome [157, 160, 161]. They 
are involved in many cellular activities, such as cell interaction, signalling, proteolysis, 
adhesion, proliferation, migration and immune response. In addition, studies have 
shown that microRNA, lipids and messenger-RNA may be secreted by the cells via 
small membranous vesicles, the exosomes and macrovesicles [162, 163]. The 
secretome is very dynamic in nature and highly sensitive to changes of the overall 
cellular state, whether at physiological or pathological circumstances. Functional 
secretory pathways are necessary for the normal physiology of human body 
therefore, any dysfunction or malfunction may lead to a various systemic problems 
including cancer [164].  
7.5.1. Role of secretome in cancer 
Cancer cells modify their protein secretion due to the continuous growth and 
adaptation to the microenvironment which is the hallmark of cancer [165]. Secreted 
proteins into the extracellular space interact between stroma and tumor cells and 
represent the main molecules involved in the intercellular communication, cell 
adhesion and invasion [166]. Since the secreted proteins are linked to the 
development of cancer, therefore, several studies have compared the secretome of 
cancer cells to the normal tissue and have seen a differential regulation of proteins 
[167]. Cancer secretome can induce a resistance mechanism to chemotherapy. 
Eckstein et al. have shown that MCF-7 cells increased the expression of 
amphiregulin, a specific ligand of the EGFR (ERBB1), when treated with cisplatin and 
found that, amphiregulin is attributed to the resistance [168]. Nodal and activin are 
necessary for cancer stem cells self-renewal in PDAC.  Interestingly, it has been 
shown that despite the stem cells, nodal and activin in the conditioned medium of 
PSCs promoted the sphere formation and invasiveness of PDAC [169]. IL-6, for 
example, is a bioactive multifunctional cytokine which promotes the accumulation of 
myeloid derived suppressor cells (MDSC) and increased the migration of pancreatic 
cancer cells via STAT-3 pathway [170, 171].  
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Previous studies have proven that IL-6 is secreted by PSCs [88] and regulated the 
immunosuppression in autoimmune diseases and cancer [139]. IL-6 induced the 
expression of IL-4 receptor on macrophages which after IL-4 binding, the STAT-6/IL-
4 axis promoted M2 phenotype of macrophages [140] which in turn induced the 
production of high amount of arginase-1 [141]. Consequently, detection and 
quantification of secretome composition could be instrumental for deciphering the 
molecular architecture of disease and thus for defining specific approaches toward 
patient management and therapy, in particular for a disease as heterogenous as 
pancreatic cancer.  
7.5.2. Role of secretome in biomarker identification  
There have been several reports about an exploration of secretomes for the 
identification of potential biomarkers [172-175]. A large portion of the secreted 
proteins – cytokines, hormones or growth factors, for example – are present at very 
low levels [161]. Sarkissian et al. analyzed the secretome of renal cell carcinoma 
(RCC) aiming at finding a biomarker. By comparing the serum samples of RCC 
patients with the healthy ones, they found an increased concentration of pro-matrix 
metalloproteinase-7 (pro-MMP-7) [176]. In another study, cancer cell secretome was 
used to identify possible biomarkers in nasopharyngeal carcinoma. Interestingly, 
three candidates of the cell line secretome, fibronectin, Mac-2 binding protein (Mac-2 
BP) and plasminogen activator inhibitor 1 (PAI-1) were highly expressed in patients 
tissues when validated [177]. Similarly, secretome of lung cancer primary cells and 
colorectal cell line secretome were used in biomarker identification [178, 179]. 
However, the sensitivity and resolution of the analysis processes were frequently 
limited.  
In serum analyses, the problem of low abundance is magnified by the presence of 
large quantities of albumin and globulins, which can obscure an analysis of rare 
proteins or mask their presence altogether. Depletion of highly abundant proteins is 
not a solution, since their removal does affect the abundance and relative ratios of 
the other proteins, too [34]. To circumvent these problems, immunofractionation with 
appropriate antibodies is often applied prior to analysis. To gather enough protein in 
such a process, however, rather large sample volumes are required. Also, 
quantification is difficult to achieve since different antibody affinities lead to different 
yields during the purification process and normalization processes are not easily 
applicable. In addition, a translation into clinical practice is difficult to achieve” [180].
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8. Materials 
8.1. Cell lines and primary cells 
Cell name Cell type Description Source / Reference 
A818-1 Cell line PDAC ATCC, Manassas, USA 
AsPC-1 Cell line PDAC ATCC, Manassas, USA 
BxPC-3 Cell line PDAC ATCC, Manassas, USA 
CFPAC-1 Cell line PDAC ATCC, Manassas, USA 
Colo357 Cell line PDAC ATCC, Manassas, USA 
Fibroblast Cell line Human fibroblast Promocell, Heidelberg, Germany 
MIA PaCa-2 Cell line PDAC ATCC, Manassas, USA 
MiaPaca2 Cell line PDAC ATCC, Manassas, USA 
Monocyte Primary monocyte Human monocyte Isolated from healthy blood 
donor 
PaCa-44 Cell line PDAC ATCC, Manassas, USA 
PacaDD119 Primary cancer cell line PDAC Dr. Pilarsky, technical 
university 
of Dresden, Germany 
PacaDD135 Primary cancer cell line PDAC Dr. Pilarsky, technical 
university 
of Dresden, Germany 
PacaDD137 Primary cancer cell line PDAC Dr. Pilarsky, technical 
university 
of Dresden, Germany 
PacaDD159 Primary cancer cell line PDAC Dr. Pilarsky, technical 
university 
of Dresden, Germany 
PacaDD161 Primary cancer cell line PDAC Dr. Pilarsky, technical 
university 
of Dresden, Germany 
PacaDD183 Primary cancer cell line PDAC Dr. Pilarsky, technical 
university 
of Dresden, Germany 
Panc-1 Cell line PDAC ATCC, Manassas, USA 
PSC Cell line Pancreatic stellate cells Dr. Ralf Jesnowsky (Mannheim 
University Hospital) 
Pt45P1 Cell line PDAC ATCC, Manassas, USA 
Raw264.7 Cell line Mouse macrophages ATCC, Manassas, USA 
SK-PC-1 Cell line PDAC ATCC, Manassas, USA 
THP-1 Cell line Human monocyte Division of Redox Regulation, 
DKFZ, Heidelberg, Germany 
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8.2. Cell culture media and solutions 
Reagent Manufacturer / provider 
DMSO cell culture grade AppliChem GmbH, Darmstadt, Germany  
Dulbecco´s phosphate buffered saline (PBS) Gibco/ Life Technologies, Carlsbad, USA  
Dulbecco's Modified Eagle Medium (DMEM) Gibco/ Life Technologies, Carlsbad, USA 
Fetal Bovine Serum (FBS), heat-inactivated Gibco/ Life Technologies, Carlsbad, USA 
Fibroblast Growth Medium (Ready-to-use) Promocell, Heidelberg, Germany 
Ficoll Histopaque-1077 Sigma-Aldrich, Munich, Germany 
Iscove's Modified Dulbecco's Medium (IMDM)  Gibco/ Life Technologies, Carlsbad, USA 
L-Glutamine 200mM Gibco/ Life Technologies, Carlsbad, USA  
Penicillin 1,000u/ml-Streptomycin 100μg/ml Gibco/ Life Technologies, Carlsbad, USA 
Phosphate buffered saline (DPBS)+ MgCl2 Gibco/ Life Technologies, Carlsbad, USA  
Phosphate buffered saline (PBS) Gibco/ Life Technologies, Carlsbad, USA 
RPMI 1640 with L-glutamine and phenol red Gibco/ Life Technologies, Carlsbad, USA 
Trypsin-EDTA (0.05%) with phenol red Gibco/ Life Technologies, Carlsbad, USA 
  
 
8.3. Chemicals, enzymes and general materials 
Reagent Manufacturer / provider 
2′,7′-Dichlorodihydrofluorescin diacetate Sigma-Aldrich, Munich, Germany 
6-Aminocaproic acid Sigma-Aldrich, Munich, Germany 
α-isonitrosopropiophenone Sigma-Aldrich, Munich, Germany 
Amidosulfobetaine-14 (ASB-14) Sigma-Aldrich, Munich, Germany 
Ammonium peroxydisulfate (APS) Sigma-Aldrich, Munich, Germany 
Benzonase Millipore Novagen, Darmstadt, Germany 
Bicine; N, N-Bis(2-hyrdoxyethyl) Biomol , Hamburg, Germany 
Blotting filter paper sheet Neolab, Heidelberg, Germany 
Blotting-Grade Blocker (non-fat dry milk) BioRad, München, Germany 
Buffy Coats Deutsches Rotes Kreuz, Mannheim, Germany 
Chloroform VWR BDH Prolabo, Bruchsal, Germany 
Cholic acid sodium salt Thermo Fisher Scientific, Bonn, Germany 
Dimethylsulfoxide (DMSO) Sigma-Aldrich, Munich, Germany  
Disodium hydrogen phosphate (Na2HPO4) Merck, Darmstadt, Germany 
DY-549 NHS-ester fluorescent dye Dyomics, Jena, Germany 
DY-649 NHS-ester fluorescent dye Dyomics, Jena, Germany 
EDTA Sigma-Aldrich, Munich, Germany 
Ethanol Sigma-Aldrich, Munich, Germany 
Glycerol Sigma-Aldrich, Munich, Germany 
Glycine Sigma Aldrich, Munich, Germany 
Glycogen, RNA grade Thermo Fisher Scientific, Bonn, Germany  
GM-CSF  Miltenyi Biotec, Bergisch Gladbach, Germany 
Griess reagent modified Sigma-Aldrich, Munich, Germany 
Halt Protease & Phosphatase Inhibitor Cocktail Fisher Scientific, Schwerte, Germany 
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Reagent Manufacturer / provider 
  
HEPES Carl Roth GmbH, Karlsruhe, Germany 
Hydrochloric acid (HCl) Merck, Darmstadt, Germany 
Interferon 13 (IL-13) Miltenyi Biotec, Bergisch Gladbach, Germany 
Interferon 4 (IL-4) Miltenyi Biotec, Bergisch Gladbach, Germany 
Interferon 6 (IL-6) PeproTech Inc., Rocky Hill, NJ, USA 
Interferon gamma (IFN-γ) Miltenyi Biotec, Bergisch Gladbach, Germany 
Isopropanol J.T.Backer, Darmstadt, Germany 
Lipopolysaccharides (LPS) Sigma-Aldrich, Munich, Germany 
MACS Running Buffer Miltenyi Biotec, Bergisch Gladbach, Germany 
M-CSF  Miltenyi Biotec, Bergisch Gladbach, Germany 
Methanol Merck, Darmstadt, Germany 
N-1-naphthylethylenediamine dihydrochloride Sigma-Aldrich, Munich, Germany 
n-Dodecyl-ß-D-maltoside GenaXXon Bioscience, Ulm, Germany  
Nitrocellulose membrane (Protran 0.45) GE Healthcare Europe, Freiburg, Germany 
NP-40 substitute Sigma-Aldrich, Munich, Germany 
Nuclease-free water Ambion, Austin, USA 
Phenylmethanesulfonylfluoride (PMSF) Sigma-Aldrich, Munich, Germany 
Phorbol 12-myristate-13 acetate (PMA) Sigma-Aldrich, Munich, Germany 
Ponceau S Serva Electrophoresis, Heidelberg, Germany 
Potassium chloride (KCl) Sigma-Aldrich, Munich, Germany  
Potassium dihydrogenphosphate (KH2PO4) Carl Roth GmbH, Karlsruhe, Germany  
Protein Standard (200 mg/mL BSA) Sigma-Aldrich, Munich, Germany 
Resazurin, sodium salt Acros Organics, Geel, Belgium 
Roti-Load 1 Carl Roth GmbH, Karlsruhe, Germany 
Sodium acetate Thermo Fisher Scientific, Bonn, Germany 
Sodium azide (NaN3) Applichem, Darmstadt, Germany 
Sodium chloride (NaCl) VWR International, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, Munich, Germany 
Sodium hydroxide (NaOH) VWR International, Darmstadt, Germany  
Spectra multicolor broad range protein ladder Thermo Fisher Scientific, Bonn, Germany  
Sulphanilamide Sigma-Aldrich, Munich, Germany 
Tetramethylenediamine (TEMED) Bio-Rad Laboratories, Munich, Germany 
Tris-HCl Sigma-Aldrich, Munich, Germany 
Triton-X100 Sigma-Aldrich, Munich, Germany 
Trizol Gibco/ Life Technologies, Carlsbad, USA 
Tween-20 Sigma-Aldrich, Munich, Germany 
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8.4. Lab equipment and disposables  
       Name Manufacturer 
12-channel-pipette Biohit proline Biohit, Helsinki, Finland 
384-well Lightcycler plates Sarstedt AG & Co., Nümbrecht, Germany 
96F Microwell plates Thermo Fisher Scientific, Bonn, Germany 
Amicon Ultra-0.5 ml Filters (MWCO 3,000 Da) Merck Millipore, Darmstadt, Germany 
Analytical balance scale 434-33 Kern, Balingen-Frommern, Germany 
Brunswick Galaxy 170S incubator New Brunswick Scientific, Steinheim, Germany  
Cell culture flasks Cell Star (T75, T175) Greiner Bio-One, Frickenhausen, Germany 
Cell culture multiwell plates (6 well, 96 well) Greiner Bio-One, Frickenhausen, Germany 
Cell Scrapper Techno Plastic, Trasadingen, Switzerland 
Centrifuge Eppendorf 5810 R Eppendorf, Hamburg, Germany 
Centrifuge Megafuge 1.0 R Heraeus Sepatech, Hanau, Germany 
Centrifuge Sigma 2K15 Sigma, Osterode am Harz, Germany 
Centrifuge Varifuge 3.0R Heraeus Sepatech, Hanau, Germany 
Cryotubes 1.0 ml Thermo Fisher Scientific, Bonn, Germany 
Electrophoresis power supply E835 Consort, Turnhout, Belgium 
Epoxysilane-coated slides SCHOTT, Jena, Germany 
FACS Canto II BD Biosciences, Heidelberg, Germany 
Falcon tubes (15 ml, 50 ml) Greiner Bio-One, Frickenhausen, Germany 
Innova CO-170 Incubator New Brunswick Scientific, Steinheim, Germany  
Leucosep tubes Greiner Bio-One, Kremsmünster, Austria 
Leica DM IRBE microscope Leica Mikrosystem, Wetzlar, Germany 
LifeECO Thermal Cycler Bioer Technology, Hangzhou, China 
Light Cycler LC480 Roche, Mannheim, Germany 
LS columns Miltenyi Biotec, Bergisch Gladbach, Germany 
MicroGrid-2 contact spotter BioRobotics, Cambridge, UK 
Millex-GS filters (0,22 µm) Millipore, Darmstadt, Germany  
Mini-Trans-Blot electrophoresis chamber Bio-Rad, Munich, Germany 
MP 230 ph-meter Mettler Toledo, Gießen Germany 
Nanodrop ND-1000 Thermo Fisher Scientific, Bonn, Germany  
Nunc Maxisorp flat-bottom 96-Well plates Thermo Fisher Scientific, Bonn, Germany 
Orbital shaker Rotamax 120 Heidolph, Schwabach, Germany 
Pasteur pipettes (230 mm) WU Mainz, Mainz, Germany 
QuadriPERM chambers Vivascience, Hannover, Germany 
Quadro MACS separator and rack Miltenyi Biotec, Bergisch Gladbach, Germany 
Roll mixer RS-TR5 Phoenix Instrument, Garbsen, Germany 
Safe lock Tubes 1.5 and 2.0 ml Eppendorf, Hamburg, Germany 
Serological pipettes (5 ml, 10 ml, 25 ml) Greiner Bio-One, Frickenhausen, Germany 
SMP3B stealth pins Telechem, CA, USA 
Syringes (2ml, 5ml, 50 ml) Terumo, Leuven, Belgium 
Tecan Infinite M200 plate reader Tecan Group, Männedorf, Switzerland 
Tecan Power Scanner Tecan Group, Männedorf, Switzerland 
Trans-Blot Turbo Transfer System Bio-rad, München, Germany 
Vi-CELL Sample Vials, 4 ml Beckman Coulter, Krefeld, Germany 
Vi-CELL XR cell viability analyzer Beckman Coulter, Krefeld, Germany 
Vivaspin 20 ultrafiltration columns (MWCO 3.000) Sartorius Biotech, Göttingen, Germany  
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Vortex-Genie 2 Scientific Industries, New York, USA 
Water bath Grant Instruments, Shepreth, UK 
Wilovert S Light Microscope Helmut Hund, Wetzlar, Germany 
 
 
8.5. Flow cytometry antibodies 
Name Manufacturer / provider 
Alexa Fluor 647 mouse anti-human CD163 (GHI/61) BD Biosciences, Heidelberg, Germany 
Alexa Fluor 647 mouse IgG1k isotype control (MOPC-21) BD Biosciences, Heidelberg, Germany 
Anti-HLA-DR-PE human (AC122) Miltenyi Biotec, Bergisch Gladbach, 
Germany 
CD206-FITC human (DCN228) Miltenyi Biotec, Bergisch Gladbach, 
Germany 
CD80-PE human (2D10) Miltenyi Biotec, Bergisch Gladbach, 
Germany 
CD86-PE human (FM95) Miltenyi Biotec, Bergisch Gladbach, 
Germany 
FITC mouse anti-human CD14 (M5E2) Miltenyi Biotec, Bergisch Gladbach, 
Germany 
FITC mouse IgG1 k isotype control (MOPC-21) BD Biosciences, Heidelberg, Germany 
PE mouse IgG1 k isotype control (MOPC-21) BD Biosciences, Heidelberg, Germany 
 
 
8.6. ELISA and western blotting antibodies 
Antibody Dilution Catalog No. Manufacturer / provider 
Anti-Collagen (COL1A1) 1:1000 sc-8784 Santa Cruz, Texas, USA 
Anti-FGF-1 1:500 sc-55520 Santa Cruz, Texas, USA 
Anti-IL-1β  1:500 sc-1251 Santa Cruz, Texas, USA 
Anti-IL-4 1:1000 ab9622 abcam, Cambridge, UK 
Anti-SERPINE 1:1000 ab154591 abcam, Cambridge, UK 
Anti-FN1 1:1000 15613-1-AP 
Proteintech group, Chicago, 
USA 
Anti-GAPDH 1:1000 CB1001 
Merck Millipore, Darmstadt, 
Germany 
Anti-α-Actinin 1:1000 A7811-100UL 
Sigma-Aldrich, Munich, 
Germany 
Anti-α-Enolase 1:1000 AP6526c Abgent, San Diego, Ca, USA 
Anti-α-SMA 1:500 H00000059-M02 Abnova, Taipei City, Taiwan 
HRP-conjugated anti-mouse 
secondary antibody 1:10000 PI-2000 Vector, Burlingame, USA 
HRP-conjugated anti-rabbit 
secondary antibody 1:10000 PI-1000 Vector, Burlingame, USA 
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8.7. Kits 
Kit name Manufacturer / provider 
Anti-human CD14 MicroBeads Miltenyi Biotec, Bergisch Gladbach, Germany 
BCA Protein Assay Kit Thermo Fisher Scientific, Bonn, Germany 
ECL Prime Western Blotting Detection Reagent GE Healthcare Europe, Freiburg, Germany  
Fast SYBR Green Master Mix Applied Biosystems, Foster City, USA 
Human IL-2 ELISA kit Abcam, Cambridge, UK 
Human IL-6 ELISA set Acris Antibodies, Herford, Germany 
Human IL-10 ELISA Kit Abcam, Cambridge, UK 
ID-1 ELISA kit Antibodies-online, Aachen, Germany 
ProtoScript First Strand cDNA Synthesis Kit New England Biolabs, Höchst, Germany 
 
 
 
8.8. Primers 
Gene Sequence (5'- 3') Company Reference 
CCL17 F- CGGGACTACCTGGGACCTC  
R- CCTCACTGTGGCTCTTCTTCG 
Biomers.net, Ulm, 
Germany 
Littlefield et al., 
2014 
GAPDH F- GAAGATGGTGATGGGATTTCCA  
R- GATTCCACCCATGGCAAATT 
Biomers.net, Ulm, 
Germany 
 
IL-1β F-TGGCAATGAGGATGACTTGTTC  
R-TAGTGGTGGTCGGAGATTCGTA 
Biomers.net, Ulm, 
Germany 
Chanput et al., 
2010 
MR 
(CD206) 
F- ACCTCACAAGTATCCACACCATC  
R- CTTTCATCACCACACAATCCTC 
Biomers.net, Ulm, 
Germany 
Littlefield et al., 
2014 
TNF-α F-CTGCTGC ACTTTGGAGTGAT  
R-AGATGATCTGACTGCCTGGG 
Biomers.net, Ulm, 
Germany 
Chanput et al., 
2010 
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8.9. Buffers and Solutions 
Buffers and Solutions   Components  
PBS 137 mM NaCl 
 27 mM KCl 
 100 mM NaH2PO4 
 17 mM KH2PO2 
 dissolved in ddH2O 
PBST 10X PBS with 0.05% (w/v) Tween 20 
10X TBS 200 mM Tris HCl 
 1500 mM NaCl 
 0.1 % (w/v) NaN3 
 Adjusted to pH 7.6  
TBST TBS with 0.05% (w/v) Tween 20 
Stacking gel buffer 1.5 M Tris.HCl 
 Adjusted to pH 6.6 
Resolving gel buffer 1.5 M Tris.HCl 
 Adjusted to pH 8.8 
SDS-PAGE running buffer 25 mM Tris-Base  
 190 mM Glycine 
 0.1 % (w/v) SDS 
Lysis buffer  1% (w/v) NP-40 
 1% (w/v) Cholic acid sodium salt 
 0.5% (w/v) ASB-14 
 0.25% (w/v) n-Dodecyl-ß-D-maltoside 
 20% (v/v) glycerol (99%) 
 50 mM Bicine (pH 8.5)  
 2mM EDTA.2Na 
 150 mM NaCl 
 1mM PMSF 
 Halt protease and phosphatase inhibitor cocktail  
 1 U/µl Benzonase 
Western blot anode buffer I 300 mM Tris-Base 
 20% (v/v) methanol 
Western blot anode buffer II 25 mM Tris-Base 
 20% (v/v) methanol 
Western blot cathode buffer 40 mM 6-aminocaproic acid  
 20% (v/v) methanol  
Spotting buffer 0.1 M NaHCO3 
 0.15 M NaCl 
 0.01 % (w/v) NaN3  
 0.0001 % (w/v) Igepal 
 0.005 (w/v) Tween 20 
 0.25 % (w/v) Dextran  
 Adjusted to pH 8.5 
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9. Methods 
Excerpts of the following text paragraphs were taken from my publications listed below: 
• Mustafa S. et al. Comparison of the tumor cell secretome and patient sera for an 
accurate serum-based diagnosis of pancreatic ductal adenocarcinoma. Oncotarget. 
2017; 8:11963-11976.  
• Mustafa S. et al., Secretome of pancreatic stellate cells promote M2 polarization of 
macrophages in pancreatic tumor microenvironment. Manuscript. 
Texts taken from these publications are enclosed in quotation marks and contribution of 
other authors are explained.  
9.1. Cell culture:  
9.1.1. Regular cell maintenance  
Pancreatic stellate cells (PSC) and all pancreatic ductal adenocarcinoma cell lines (See 
the material part; Cell lines and primary cells) were cultured in IMDM medium 
supplemented with 10% FBS and 1% Pen/Strep antibiotics. The cells were detached 
using Trypsin-EDTA and passaged at least twice a week depending on the growth rate. 
Raw264.7 macrophages were grown in complete DMEM medium including 10% FBS and 
1% Pen/Strep antibiotics. Raw264.7 cells were detached every three days by cell 
scrapers and seeded in new flasks. THP-1, human monocyte cells were grown in 
RPMI1640 medium containing 10% FBS and 1% Pen/Strep. Since THP-1 cells are 
suspension, 2-3ml of the cells were taken from the suspension and re-cultured in new 
media every three days. Similarly, isolated primary human monocytes from blood were 
cultured in RPMI1640 medium. All cell types were incubated in standard humidified 
condition at 37°C with 5% CO2 in the dark. All cell lines were previously authenticated and 
checked for mycoplasma contamination. 
9.1.2. Collection of conditioned media and activation of PSCs 
PSCs were activated as defined before [181]. Briefly, PSCs were grown in complete IMDM 
medium until they reached a sub-confluent state of 75-80%. The sub-confluent cells were 
then washed twice with pre-warmed PBS to remove remaining serum. The cells were 
afterwards starved for 12 h in IMDM serum-free medium (IMDM-SFM) to synchronize cell 
growth followed by treating with 10 ng/ml TNF-α for 24 h. Subsequently, PSCs (treated 
and non-treated) were washed twice with pre-warmed PBS and once with SFM to remove 
traces of TNF-α. After that, the cells were incubated in fresh IMDM-SFM for 48 h. PDAC 
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cell lines and fibroblast cells were not activated, therefore, when the cells reached 85-90% 
confluence, were washed twice with PBS and once with SFM. The cells were 
subsequently cultured for further 48 h in SFM, then the condition media (CM) were 
collected and centrifuged at 3,000 g for 10 min at 4˚C to remove cell debris. Three different 
methods were used to concentrate the conditioned media which were trichloroacetic acid 
(TCA) precipitation, dialysis with lyophilization and ultrafiltration using Vivaspin-20 
centrifugal tubes. However, ultrafiltration with centrifugal tubes found to be the best 
method for obtaining proteins in high quality with respect to reproducibility, concentration 
and integrity. Therefore, Vivaspin-20 tubes with a molecular weight cut-off value of 3 kDa 
were used according to the manufacturer’s protocol. In brief, the Vivaspin-20 tubes were 
filled with 20 ml CM and centrifuged at 5,000 g at 4°C for 2 h in a swing-bucket centrifuge. 
Following twice buffer exchange with 0.1M Bicine (pH 8.5), the concentrated CM, which is 
now called secretome, was either used directly in cellular experiments or stored at (-80°C) 
until use. The protein concentration was determined using Bicinchoninic Acid (BCA) 
protein assay reagent kit. PSC activation was checked with the western blot depending on 
the expression of alpha smooth muscle actin (α-SMA) and fibronectin (FN-1).  
9.1.3. Collection and handling of serum samples 
Excerpts of this paragraph were taken from my publication. “For all serum samples 
analyzed, written informed consent was given by the patients and healthy donors. Ethical 
approval was obtained from the local ethics committee at the University of Heidelberg; 
ethics vote 159/2002 of 28 December 2007”. For the serum-based diagnosis two different 
serum groups were selected and analyzed separately as training and test sets. “The 
training set serum samples were composed of 47 patients with pancreatic ductal 
adenocarcinoma (PDAC), 18 people with chronic pancreatitis (CP) and 27 age and sex-
matched healthy individuals. Whereas the test set was composed of 25, 25 and 22 serum 
samples, respectively. Patient diagnosis was based on histological analyses and the 
disease stage was determined by classification of tumor, node and metastasis (TNM). 
Exclusion criteria had been applied to patients, who had secondary conditions such as 
autoimmune, inflammatory or infectious diseases. The serum samples were stored 
immediately at -80°C until use” [180]. 
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9.1.4. Monocyte isolation 
Human monocytes were isolated by density gradient centrifugation. Accordingly, blood 
samples from healthy donors were diluted with PBS (1:4) and applied onto 50ml Leucosep 
tubes containing 15ml pre-warmed Ficoll Histopaque. Blood samples with the ficoll were 
centrifuged at 1,000g for 20 min at room temperature without break. After that, human 
peripheral blood mononuclear cells (PBMC) were collected and washed twice with PBS 
and resuspended in MACS buffer. Subsequently, total cell number was counted, and 
monocytes were isolated using CD14+ magnetic beads according to the manufacturer’s 
instructions. Briefly, PBMCs in MACS buffer were mixed gently with anti-CD14+ magnetic 
beads for 15 min at 4°C. Afterwards, the labeled cells were applied onto the calibrated 
MACS LS columns in the magnet separator. The cells were washed three times and were 
Figure 3. Workflow of PSC activation, collection of conditioned media of PDAC and fibroblast 
cell line and secretome extraction. 
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eluted with 5ml MACS buffer. The purified monocytes were counted and cultured overnight 
in serum free RPMI-1640 medium to improve cell attachment. 
9.1.5. Monocyte differentiation to macrophages 
The isolated human monocytes were cultured in RPMI-1640 complete medium with 100 
ng/ml GM-CSF, 20 ng/ml M-CSF or treated with the secretome of PSC and PDAC cells to 
differentiate to macrophages. The differentiation of THP-1 monocytic cell line is described 
before [182]. Briefly, THP-1 monocytes at a concentration of 0.5 x 106 Cell/ml were 
differentiated to macrophages using 100 ng/ml PMA for 48 h followed by washing twice 
with RPMI and 24 h resting stage in PMA-free RPMI1640 medium. Thus, monocytes were 
differentiated to macrophages and the differentiation were later confirmed based on 
microscopic cell phenotype observation and HLA-DR expression. Hereafter, the 
macrophages were polarized with 100 ng/ml LPS plus 20 ng/ml IFN or with 20 ng/ml 
IL4/13 to classically activated (M1) or alternatively activated (M2) macrophages, 
respectively. For the cellular interactions, the macrophages were treated with the 
secretome of different stromal cells in later experiments. 
 
9.1.6. Treatment of macrophages with PSC and PDAC secretome 
The freshly isolated human monocytes (1x106 cells/ml) were cultured in RPMI 1640 for 
seven days with the secretome of activated or non-activated PSCs and PDAC cell lines. 
Meanwhile, the macrophages were polarized with 100 ng/ml LPS and 20 ng/ml IFN or 
with 20 ng/ml IL-4/13 to M1 and M2 types respectively as positive controls. The stimuli, 
including the secretome, and the media were changed every two days. The differentiated 
macrophages from the THP-1 cells were treated for 48 h with the standard stimuli or with 
the secretome of activated and non-activated PSCs. Macrophage polarization was 
determined depending on the cell surface markers expression, cytokine secretion, 
arginase activation and nitric oxide production. Furthermore, effect of IL-6 was evaluated 
in macrophage polarization targeting surface marker expression. 
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9.2. Protein analysis with antibody microarray 
9.2.1. Antibody microarray production 
Two different sets of antibody microarrays were used in protein analysis which have been 
used previously [180, 181]. The first set consisted of 735 antibodies whereas the second 
one composed of 1439 antibodies including positive and negative controls as well as 
positional marker molecules. The arrays were produced as described previously in detail 
[183]. Briefly, 5µg of each antibody was added to the spotting buffer which composed of 
100 mM Bicine buffer (pH 8.5) containing 0.005% Tween-20, 0.05% sodium azide, 5% 
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Conditioned media 
 
7 days   incubation 
PSC_TNF 
Conditioned 
medium 
 
PSC_Ctrl 
Conditioned 
medium 
 
PDAC 
Conditioned 
medium 
 
Antibody 
microarray 
 Real time PCR 
FACS 
Macrophage 
Figure 4. Workflow of macrophage incubation with the secretome of PSCs and PDAC 
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trehalose, 5 mM magnesium chloride and 137 mM sodium chloride. The antibodies were 
spotted in quadruplicates on epoxysilane-coated glass slides using the contact printer 
MicroGrid-2 and SMP3B pins at 55-65% humidity. After the spotting, the slides were kept 
at room temperature at the same humidity level for 24 h before they were stored in a dry 
place at 4°C. 
9.2.2. Protein extraction  
Cellular proteome was extracted using lysis buffer as reported previously [184]. The lysis 
buffer composed of 50 mM Bicine buffer (pH 8.5) containing 20% glycerol, 1.0 mM 
magnesium chloride, 5.0 mM EDTA, 1.0 mM phenylmethanesulfonyl fluoride, 1.0 IU/ml 
benzonase, Halt Protease and Phosphatase Inhibitor Cocktail, 0.5% Nonidet P-40 
substitute, 1.0% Cholic acid, 0.25% n-dodecyl-β-maltoside and 0.5% amidosulfobetaine-
14. Briefly, cells were washed with cold PBS then minimal volume of lysis buffer was 
added to each flask and incubated on ice for 30 min.  The cells were subsequently 
collected with cell scraper and pipetted up and down with a syringe through a 23G needle 
followed by centrifugation at 18,000g for 20 min at 4°C. Subsequently, supernatants were 
transferred to fresh microcentrifuge tubes and total protein concentration was determined 
using Bicinchoninic Acid (BCA) protein assay reagent kit according to manufacturer’s 
instructions.  
9.2.3. Protein labeling 
For protein labeling, cellular proteome, secretome and serum samples were adjusted with 
0.1M Bicine buffer to the same concentrations. The samples were labelled with the 
fluorescent NHS-ester dye DY-649P1 (Cy-5) in a molar ratio of 7.5 (dye/protein) in dark 
eppendorf tubes and were shaken at 4°C for 2 h. Afterwards, the unlabeled fluorescent 
dye was quenched by adding 10% glycine with a constant shaking for 20 min. For the 
reference background, cellular proteome were pooled and labeled with DY-549P1 (Cy-3) 
as described previously [185]. For serum analyses, a pool reference was prepared from all 
samples using the same concentration of each sample.   
9.2.4. Microarray incubation, scanning and image processing 
The procedure of antibody microarray incubation is previously described [183]. Before the 
incubation with the labeled samples, the arrays were equilibrated at room temperature for 
30 min followed by washing twice with TBST. The arrays were then blocked with 5ml of 
10% non-fat dry milk, prepared in TBST, in quadriPERM chambers and left on a shaker at 
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room temperature for 3 h. The arrays were subsequently washed with TBST and 
incubated overnight with 50 µg of the labelled samples and pool reference in 1% milk at 
4°C with constant shaking. The arrays were washed four times with TBST and once with 
distilled water followed by drying in a ventilated oven at 25°C. Consequently, arrays were 
scanned using a Tecan power scanner at constant laser power and the resulting images 
were analyzed with GenePix Pro 6.0 software. 
9.3. Flow Cytometry 
Flow cytometry was performed on live macrophages. Briefly, cells were detached from the 
culture flask with trypsin-EDTA solution and were washed in PBS. Subsequently, the cells 
were labeled with the fluorochrome-conjugated antibodies CD86-PE, CD206-FITC, 
CD163-Alexa Fluor647 and their corresponding isotype in FACS buffer (500ml PBS pH 7.4 
containing 5% FBS, 250mg sodium azide and 2ml of 0.5M EDTA) for 30 minutes at 4°C. 
The labeled cells were washed twice in PBS afterwards and FACS analysis was 
performed with a FACS Canto II. At least 10,000 events were collected per sample and the 
data were analyzed using flowJo software V.10. Mean fluorescence intensity (MFI) of 
seven different experiments were calculated by dividing the Geometric mean of each 
marker relative to their isotype negative controls.  
9.4. Immunoblotting 
Depending on the molecular weight of the examined proteins, SDS gels (1.0 mm thick) 
were prepared with 5% acrylamide / bisarcylamide in the stacking gel and 10-12% of the 
resolving part. Protein concentration of the cellular proteome, secretome and serum 
samples were adjusted and mixed with an appropriate amount of reducing loading buffer 
(Roti-Load) followed by boiling at 96°C for 5 min. The reduced samples and the protein 
ladder (multicolor broad range protein ladder) were loaded onto the gel. Electrophoresis 
was performed initially at 60 V until the dye reached the resolving gel then, the power was 
changed to 150 v until the dye reached the end of the gel. The proteins were transferred 
from SDS-PAGE onto nitrocellulose membranes using Trans-Blot Turbo transfer system 
using standard semi-dry protocol. Briefly, the Whatman filter papers were soaked in anode 
I, anode II and cathode buffer and the membrane was activated in anode II buffer. The 
sandwich was assembled, and the transfer carried out at 25V, 1.0 A for 30min. The protein 
transfer was confirmed using Ponceau stain (0.1% (w/v) Ponceau in 5 % (v/v) acetic acid) 
followed by washing with TBST till the stain disappeared. Afterwards, the membranes 
were blocked with 5% milk, prepared in TBST, for one hour and washed again twice with 
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TBST. Subsequently, the membranes were incubated with the diluted primary antibodies 
in 5% milk overnight with gentle shaking. The blots were then washed twice with TBST 
and incubated with HRP conjugated secondary antibody for 60 min at room temperature. 
Later, the blots were washed twice, and the proteins were detected by enhanced 
chemiluminescence (ECL) detection solution and visualized using Luminescent Image 
Analyzer LAS 4000 mini machine coupled with a CCD camera. Densitometry of the 
images were assessed by ImageJ (NIH) software, whereby the expression of each target 
protein was normalized to the house keeping protein.  
9.5. RNA isolation 
Total RNA was extracted from the non-treated macrophages, M1 and M2 positive controls 
as well as from macrophages which were treated with the secretome of PSCs using TRIzol 
LS reagent according to the manufacturer’s instructions. Briefly, 106 cells were 
resuspended in 1 ml Trizol and vortexed. The lysate was mixed with 200 μl chloroform and 
were shaken vigorously then incubated at room temperature for 2-3 min. The tubes were 
afterwards centrifuged at 12,000 g for 15 min at 4 °C, leading to phase separation. The 
aqueous phase (colorless) was carefully pipetted into a new tube containing 500 μl ice-
cold isopropanol and 2µl glycogen. The tubes were carefully mixed and incubated at -20 
°C for 60 min followed by centrifugation at 12,000 g for 10 min at 4 °C. The RNA pellets 
were then washed with 1ml of 70 % (v/v) ethanol and dried at room temperature for 15 
min. The pellets were finally resuspended in 50µl pre-warmed nuclease-free water and 
incubated at 60 °C for 10 min and RNA concentration was measured with the NanoDrop 
ND-100 spectrophotometer. 
9.6. cDNA synthesis and Real-Time PCR 
cDNA was synthesized from 700ng of total RNA of macrophages using ProtoScript First 
Strand cDNA Synthesis Kit according to the manufacturer’s instructions. The subsequent 
qRT-PCR reaction (20µl) containing 2µl of each cDNA template, 2µl of both forward and 
reverse primers, 10µl fast Syber Green master mix and 6µl nuclease free water was 
performed on LightCycler 480. The reaction was performed as follows: enzyme activation 
at 95 °C for 1 min, followed by 40 cycles of amplification (95 °C for 10 s and 60 °C for 35 
s). All samples were run in triplicate and relative expression of TNF-α, IL-1β, Mannose 
receptor (CD206) and CCL17 were calculated by ΔΔCt method using GAPDH as an 
internal control reference. 
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9.7. ELISA 
The serum samples and secretome and proteome of the activated and non-activated 
PSCs were analyzed with ELISA. IL-2, IL-6, IL-10 and ID-1 were analyzed using 
commercial ELISA kits according to the manufacturer’s instructions (see the kits in the 
materials part). However, fibronectin and collagen in the secretome of PSCs were 
analyzed using primary antibodies in a standard ELISA protocol. Briefly, five technical 
replicates of 20µg cell secretome were coated in Nunc-MaxiSorp 96-well plates overnight. 
After immobilization, the residual samples were discarded, and the plates were blocked 
with 5% milk in PBST for 3 h. After subsequent washing, the plates were incubated 
overnight with the diluted primary antibodies at 4°C. After that, the plates were washed 
and incubated with the HRP-conjugated secondary antibody at room temperature for 1 h. 
Eventually, the plates were washed followed by the addition of TMB substrate and then the 
absorbance was read at 540nm.  
9.8. Proliferation assay  
For the proliferation assay, 1x104 cells/well (Panc-1 and BxPc-3) were seeded in the cell 
culture 96 well plates in IMDM. The medium was removed, and the cells were starved 
overnight. Afterwards, the cells were treated with the conditioned media (CM) of the 
activated and non-activated PSCs, the CM of treated macrophages with the PSCs 
secretome and the positive and negative controls, containing 20µg/ml Resazurin reagent a 
final concentration. The cells were then incubated for 1 h at 37°C and subsequently 
relative fluorescence was measured at 544nm excitation / 590 nm Emission, using Infinite 
M200 plate reader. 
9.9. Nitric oxide (NO) production assay 
The presence of nitrite, a stable oxidized product of nitric oxide (NO), was determined in 
the cell supernatant of activated and non-activated PSCs as well as in the supernatant of 
macrophages which were treated with the conditioned media of activated and non-
activated PSCs using Griess reagent modified [186]. Briefly, equal volumes of the cell 
supernatant and Griess reagent were mixed in 96-well plates and incubated for 15 min at 
room temperature protected from light. Afterwards, the absorbance was measured at 
540nm and the results were calculated based on a standard curve produced by the serial 
dilution of NaNO2. 
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9.10. Reactive Oxygen Species (ROS) measurement  
Reactive Oxygen Species (ROS) was measured in the PSCs activated with TNF-α and in 
the macrophages which were treated with the conditioned media of PSCs. The cells were 
cultured in 96 well plates until 80-85% confluency. The medium was removed, and the 
cells were washed with PBS. Afterwards, the cells were treated with the stimuli or with the 
conditioned media of PSCs as stated above. The stimulus and conditioned media were 
removed from the plates and the cells were washed carefully with PBS. Consequently, the 
cells were incubated with serum and phenol red free medium containing 50µM DCFH-DA 
(prepared in DMSO) for 30min at 37°C in the dark. After incubation, the cells were washed 
twice with PBS and fluorescence was measured with excitation at 488nm and emission at 
530nm using fluorescence plate reader. 
9.11. Arginase activity measurement 
Arginase activity was measured in macrophages as described previously [187]. In short, 
treated macrophages lysed with Arginase lysis buffer (0.1% (v/v) Triton X-100 in 25 mM 
Tris–HCl pH 8.0) and protein concentration was measured using BCA kit. To measure total 
arginase,100 µl of lysis buffer containing the cell lysates were mixed with 10 µl MnCl2 
(100mM) and incubated at 55 °C for 10 min. After that, 100 µl of 0.5 M arginine was added 
to each microfuge tube and the samples were incubated at 37°C for 1 hr. Subsequently, 
the reaction was stopped by adding 800 µl acid mixture (1:3:7 (v/v/v) H3PO4: H2SO4: 
ddH2O) then 40µl of 6% α-isonitrosopropiophenone (α-ISPP) were added to each reaction 
to generate urea. Thereafter, the samples and the standards were incubated at 95°C for 
40min then cooled down at RT. Eventually, 200µl of each sample was added to 96-well 
plates (five technical replicates each) and absorbance was measured at 550nm. 
9.12. Statistical analysis 
Statistical analysis was performed using GraphPad prism 6.0. Data were represented as 
mean values with the respective standard deviations of at least three independent 
experiments or biological replicates. Differences between treatments were calculated (as 
indicated in the figure legends) where P-Values <0.05 considered significant. The 
statistical analysis of microarray data is taken from Mustafa et al. 
“The statistical analysis of microarray data was conducted with the Chipster software 
package (v1.4.6, CSC, Finland). The data were presented as the median of the signal 
intensities in the red (DY-649) and green (DY-549) channels, respectively. The coefficient 
of variance for the pool reference was less than 10% across all tested microarrays. Signal-
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to-noise ratio (SNR) was calculated as (median foreground vs. median background) / 
(standard deviation of background) for both the red and green channels. The Loess 
approach was used for data normalization with background correction offset (0, 50) of the 
normexp [188]. Two-group test between normal and cancer cells was done using the 
empirical Bayes test with Bonferroni-Hochberg adjustment for multiple testing [189]. A p-
value of 0.05 or less was considered significant. Array quality was assessed using the 
ordinate method Detrended Correspondence Analysis [190]. In addition, array results were 
clustered using their Pearson correlations and a dendrogram was constructed using the 
Average Linkage method”.  
“For a prediction of the functional aspects of the differentially expressed proteins, the 
Ingenuity Pathways Analysis (IPA) software package (version 6.3; Ingenuity Systems, 
Redwood City, USA) was applied. Prediction of function activation of inhibition was 
calculated within IPA using z-score method. Component annotation was mapped using the 
web-based Gene Ontology tool of UniProt (www.uniprot.org). The Ingenuity software also 
permitted a literature analysis with respect to the biomarker status of particular proteins. 
The sensitivity and speciﬁcity of discriminating patient groups were calculated with support 
vector machine (SVM) algorithms in R programming [191] with a threshold level of zero. 
The samples were divided into a training set and a test set. Using the SVM decision 
values, a receiver operating characteristics (ROC) curve and the respective area under the 
curve (AUC) value were calculated. To define biomarker signatures, a leave-one-out 
cross-validation procedure was applied. A linear kernel was used, and all the other 
parameters were set as default to avoid overfitting. Each time one sample is removed from 
the training set, the remained samples were analyzed as follows: each protein in the 
remained samples was removed in turn, the remaining protein groups were analyzed with 
Wilcoxon test. The most significant group was chosen and used for calculating a SVM 
decision value with the left-out sample. The same strategy was used with the chosen 
group until only one protein is left. By this approach, a candidate biomarker list was found, 
which was then evaluated with the test set” [180]. 
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10. Results 
The results which were obtained from my publications were clearly referenced and 
contributions of others were clarified in all figures which were not created by myself.  
 
• Mustafa S. et al. Comparison of the tumor cell secretome and patient sera for an 
accurate serum-based diagnosis of pancreatic ductal adenocarcinoma. 
Oncotarget. 2017; 8:11963-11976.  
• Mustafa S. et al., Secretome of pancreatic stellate cells promote M2 polarization 
of macrophages in pancreatic tumor microenvironment. Manuscript. 
The first part of the results is dealing the activation of pancreatic stellate cells by the 
pro-inflammatory factor TNF-α and characterizing the secretome with antibody 
microarrays. Afterwards, the secretome is validated and applied in different 
experimental setups to investigate cellular interactions. In the second part, the PSCs 
and PDAC secretome were used as cell stimuli on human monocytes to study 
changes in macrophage’s polarization and function as well as to define the changes 
in macrophages cellular proteome and secretome. Moreover, the impact of the 
conditioned media of the treated macrophages were then explored in pancreatic 
cancer cell proliferation. The third part shows the significance of PDAC cell 
secretome in biomarker discovery which was validated with serum samples of 
healthy donors and patients with pancreatic cancer. 
 
10.1. PSC activation, validation and secretome functional characterization 
The aim of the project was to investigate the role of secretome in cellular 
communications in the pancreatic tumor microenvironment. Therefore, to imitate the 
tumor environment, PSCs were activated and the secretome of PSCs and PDAC 
were collected and used as the cellular stimulant. We have previously investigated 
the influence of pro-inflammatory factors such as TNF-α, CCL-4, IL-6 and FGF-2 on 
biological functions of PSC and shown that TNF-α is the most potent factor that 
activates the PSCs and changes the secretome profile [181]. Hence, throughout the 
thesis, PSC_TNF stands for the activated PSCs with TNF-α whereas the PSC_Ctrl 
represent the non-activated PSCs which were only incubated in serum free medium.  
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10.1.1. Activation of PSC with TNF-α  
To synchronize cell growth, PSCs were first starved for 12 h in serum free medium 
then incubated with TNF-α for 24 h. It has been shown that PSCs highly express 
alpha-smooth muscle actin (α-SMA), fibronectin (FN-1), collagen, vimentin and 
desmin when activated [192]. Analyzing the cellular proteome of activated and non-
activated PSCs, using western blot, showed a higher expression of FN-1 and α-SMA 
in activated PSCs compared to the non-activated control (Figure 5A & B). It has been 
shown that PSCs remain activated after chemotherapy [193] and for PDAC patients, 
gemcitabine is the main chemotherapeutic agent. Correspondingly, PSCs treated 
with the gemcitabine highly expressed α-SMA and FN-1 suggesting the possibility of 
PSC activation by therapeutic agents (Figure 6A & B). Different therapeutic agents 
might be used in PDAC treatment, either alone or with other factors therefore, the 
secreted molecules by PSCs could not be similar. Additionally, because chronic 
inflammation is thought to be the onset of PDAC so, activation of PSCs by the 
proinflammatory factors is investigated in this thesis.  
 
 
Figure 5. The expression of FN-1 and α-SMA after activation of pancreatic stellate cells 
(PSC) with TNF-α.  Immunoblots with the respective densitometry showed the expression of 
fibronectin-1 (A) and alpha-smooth muscle actin (α-SMA) (B) as activation marker of PSCs after 
stimulation with TNF-α (10ng/ml) compared to the untreated control cells (Ctrl). The expression 
level of target proteins was normalized to the level of internal control, GAPDH. Expression of α-
SMA was analyzed by Maureen Buschman. 
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Figure 6. Effect of gemcitabine on PSC activation. Immunoblots with the respective densitometry 
showing the expression of α-SMA (A) and fibronectin (B) by PSCs treated with 2µg/ml gemcitabine 
and TNF-α for 24 h. The experiments were done with Maureen Buschman and Hannah Kempf. 
 
 
10.1.2. Characterization and validation of PSC secretome  
The secretome of five biological replicates of the activated and non-activated PSCs 
were analyzed by antibody microarrays. This analysis indicated more than 300 
differentially regulated proteins which are reported previously with the detailed 
activation conditions and p-values [181]. The regulated proteins had different cellular 
locations when analyzed by IPA (Figure 7). The IPA analysis showed that 18% of the 
markers were secreted into extracellular space while 17% were originated from the 
plasma membrane. The other proteins were from cytoplasm and nucleus. Moreover, 
the antibody microarray data of the PSC secretome was validated by ELISA and 
immunoblotting (Figure 8). In agreement with the microarray data, immunoblot results 
confirmed the upregulation of IL-4, IL-1β, FGF-1, SERPINE, FN-1 and Collagen in 
the secretome of activated PSCs (Figure 8A, B and C). Similarly, ELISA results have 
shown that IL-6, collagen and fibronectin were significantly upregulated in the 
secretome of activated PSCs compared to the non-activated one (Figure 8D, E and F 
respectively).  
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Interestingly, the disease and functional annotation analysis performed by IPA 
predicted increased activation of immune cells by the PSC secretome (Table 1). In 
such analysis the top diseased and functions with the top activation z-scores were 
associated to immune response of cells and phagocytes, lymphocyte homeostasis, 
recruitment and differentiation of mononuclear leukocytes and cell viability of 
leukocytes. Moreover, the functional analysis indicated that some of the molecules 
such as CSF-2, FN-1, IL-2RG, IL-6 and TNF were associated with macrophages 
activation, induction and migration (Table 2).  The analysis predicted the potential 
influence of PSC secretome on the function of immune cells, the interaction which is 
particularly investigated in detail. The predicted functional analysis of the activated 
PSC secretome on cell death and proliferation by IPA showed that 136 proteins are 
involved in increasing tumor cell line proliferation and 122 others are involved in cell 
viability (Table 3). In contrast, the molecules related to apoptosis, necrosis and cell 
death had a negative z-score indicating the down regulation of those markers in the 
secretome of PSC. 
 
 
 
 
Figure 7. Percentage and cellular location of the secreted proteins by activated PSCs. The 
profiled secretome data by antibody microarrays was analyzed by Ingenuity pathway analysis which 
was performed by Aseel Marzoq and the figure was created by myself. 
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Table 1. Downstream effects analysis of activated PSC secretome. List of the most relevant 
diseases and functions, their p-values, the predicted activation states with activation z-scores higher 
than 2 and the number (#) of involved molecules that are associated with each disease or function and 
were regulated in the PSC secretome. 
Diseases or Functions Annotation p-Value 
Predicted 
Activation State 
Activation z-
score 
# Molecules 
Immune response of cells 1.73E-27 Increased 3.045 59 
Immune response of leukocytes 4.32E-20 Increased 2.989 37 
Lymphocyte homeostasis 2.11E-22 Increased 2.892 53 
Immune response of phagocytes 1.74E-18 Increased 2.879 29 
T cell development 9.03E-21 Increased 2.851 49 
Transmigration of cells 3.02E-18 Increased 2.694 26 
Hematopoiesis of mononuclear leukocytes 2.46E-25 Increased 2.691 63 
Homeostasis of leukocytes 8.32E-23 Increased 2.578 54 
Response of myeloid cells 1.72E-17 Increased 2.573 29 
Differentiation of mononuclear leukocytes 5.22E-26 Increased 2.558 64 
Quantity of lymphatic system cells 6.15E-33 Increased 2.517 75 
Migration of myeloid cells 5.17E-25 Increased 2.506 33 
Quantity of lymphoid cells 1.54E-27 Increased 2.394 66 
Cellular homeostasis 1.71E-34 Increased 2.332 111 
Chemotaxis of myeloid cells 3.39E-21 Increased 2.303 37 
Quantity of lymphocytes 8.33E-27 Increased 2.274 65 
Recruitment of mononuclear leukocytes 8.65E-23 Increased 2.199 27 
Activation of antigen presenting cells 1.99E-17 Increased 2.094 34 
Cell viability of leukocytes 1.5E-24 Increased 2.055 38 
Figure 8. Validation of secreted proteins by PSCs after stimulation with TNF-α. (A, B and C) 
Immunoblots show the differential regulation of different proteins in the PSCs secretome. ENO-1 was 
used as an internal control. IL-6 (D), collagen (E) and fibronectin (F) were validated by ELISA. Data 
were analyzed using an unpaired, non-parametric Mann-Whitney test. **P<0.005, ***P<0.0005. IL-6 
validation was performed by myself whereas the other experiments were conducted by Aseel Marzoq. 
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Table 2. Functional annotation of some molecules upregulated by the TNF-α stimulation based 
on ingenuity pathway analysis (IPA).  The listed markers are the relevant proteins with their p-
Values and predicted functional effects on macrophages. 
Protein symbol P. Value Functions 
CSF2 2.50E-05 Activation of macrophages 
FN1 0.000166 Activation of macrophages and cell movement of monocytes 
VEGFC 8.80E-05 Angiogenesis 
IL2RG 0.000874 Induction of macrophage 
CXCL10 0.002139 Activation and cell movement of macrophages 
IL2 0.000281 Activation of macrophages, cell movement of monocytes and angiogenesis 
IFNg 0.000223 Migration of macrophages 
IL6 0.000166 Activation of macrophages and cell movement of monocytes 
MMP10 0.002299 Migration of macrophages 
TNF 0.000179 Activation, cell movement of macrophages and infiltration by macrophages 
IGF2 0.010064 Angiogenesis 
MMP12 0.001377 Migration and cell movement of macrophages 
CXCR5 0.004296 Activation of macrophages 
 
 
Table 3. Predicted functional effect of activated PSC secretome on cell death and proliferation. 
List of the relevant functions and the predicted activation state with the number of molecules involved. 
Function Annotation p-value Activation z-score # Molecules 
Apoptosis 2.24E-60 -0.797 177 
Necrosis 3.1E-59 -0.28 176 
Cell death 3.71E-59 -0.046 197 
Cell proliferation of tumor cell lines 5.31E-54 1.604 136 
Cell viability 1.03E-51 1.886 122 
Cell survival 1.5E-50 1.916 124 
Migration of cells 8.58E-50 1.114 143 
Invasion of cells 1.93E-37 1.666  87 
 
 
10.1.3. Reactive oxygen species (ROS) measurement in the PSC  
The intracellular ROS was measured in the activated and non-activated PSCs using 
the non-fluorescent substrate dichlorofluorescein (H2DCF). The intracellular level of 
ROS was significantly increased in the PSCs treated with TNF-α after 24 h (but not 
after 6 h) compared to the non-treated cells (Figure 9). This confirmed the activation 
Results 
49 
 
of PSCs with TNF-α as it is known that TNF-α is inducing reactive oxygen species 
[194] which is a known PSC activating agent [80]. 
 
 
 
10.1.4. Secretome of activated PSC increased cancer cell proliferation 
We investigated the paracrine effect of stromal cells secretome on tumor cells, to see 
whether the secretome of PSCs have a role in cancer cell proliferation. The 
pancreatic cancer cell line BxPC-3 was treated with the secretome of activated and 
non-activated PSCs for 24 and 48 h then cell proliferation was determined using the 
resazurin fluorescent dye. The secretome of activated PSC, in comparison to the 
non-activated PSC, significantly increased BxPC-3 cell proliferation in both 24 h and 
48 h time points (Figure 10). However, the secretome of non-activated PSCs 
increased the BxPC-3 cell proliferation only after 24 h in comparison to the untreated 
control but, its effect has come to an end at the 48 h time point. The significant impact of 
activated PSCs secretome on cell proliferation is probably due to the availability of different 
types of growth factors that promote survival and proliferation of cancer cells as indicated in 
the IPA analysis (Table 3).  
Figure 9. Reactive oxygen species (ROS) production by PSCs. ROS was measured in the PSCs 
treated with TNF-α (10 ng/ml) for 6 and 24 h and the non-treated controls. Compared to the non-
treated PSCs, stimulation with TNF-α significantly increased ROS production after 24 h. Data were 
analyzed using two-tailed, unpaired t-test and results were expressed as mean values with the 
standard deviation. ****P<0.0001, ns=not significant 
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Effect of IL-6 on PDAC proliferation 
The secretome of activated PSCs increased PDAC proliferation (Figure 10) 
compared to the non-activated PSCs. Since IL-6 was significantly upregulated in the 
PSC secretome, the effect of different concentrations of IL-6 on Panc-1 cells 
proliferation was evaluated. Cell proliferation was measured with the resazurin 
fluorescent dye and compared to the negative and positive controls (Figure 11). 
However, cell proliferation significantly increased only when 10% FBS was used 
whereas IL-6 didn’t show significant effect on cell proliferation. Thus, the results 
indicating that IL-6 in the secretome of PSCs is not the molecule that have increased 
PDAC cell proliferation.  
Figure 10. Regulation of pancreatic ductal adenocarcinoma cell proliferation by the secretome 
of PSCs. BxPC-3 cells were treated with the secretome of activated (PSC_TNF), non-activated PSCs 
(PSC_Ctrl) and no treatment (NT) for 24 and 48 h in quadruplicates. Relative cellular proliferation was 
determined using fluorescent resazurin dye after one-hour incubation. Data were analyzed using one-
way ANOVA, Bonferroni's multiple comparisons test. **P<0.005, ***P<0.0005, ****P<0.0001, ns=not 
significant 
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10.2. PSC and macrophage cellular interaction at the secretome level 
The impact of the PSCs and PDAC secretome on the function and polarization state 
of macrophages were investigated. Monocytes were isolated from healthy human 
blood by density gradient centrifugation yielding a purity of monocytes of 93% of total 
PBMC expressing 100% CD14 marker (Figure 12) which was analyzed by flow 
cytometry. Monocyte-derived human macrophages were then treated with the 
secretome of activated and non-activated PSCs and PDAC secretome for seven 
days with two days interval changing the media and the stimuli. Because of the 
genetic variations among different donors, monocytes stimulation may differ among 
different blood donor, therefore, positive controls were always included in all 
experiments. This was necessary to see the functional response of isolated 
monocytes to the stimuli and to overcome false-positive results. Monocytes were 
treated with LPS and IFNγ for the M1 positive control whereas IL4, IL-10 and IL-13 
were used to stimulate M2 polarization. 
Figure 11. Box plots showing the proliferation of pancreatic ductal adenocarcinoma cells by IL-
6. Panc-1 cells were treated with IL-6 for 24 h in quadruplicates. Relative cellular proliferation was 
determined using fluorescent resazurin dye after one-hour incubation. Data were analyzed using a two 
tailed, unpaired t-test. ***P<0.0005, ns=not significant. 
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10.2.1. Differentiation of monocytes to macrophages 
The differentiation of monocytes to macrophages was first confirmed either 
phenotypically, by observing cell structure changes or based on the expression of 
HLA-DR antigen (Human Leukocyte Antigen – antigen D Related). Monocytes 
treated with different stimuli or the PSC secretome, were checked for differentiation 
before the final detachment for analysis. Microscopic observation of the monocytes 
treated with M-CSF, GM-CSF and the PSC secretome indicated the differentiation of 
monocytes to different types of macrophages (Figure 13.) Microscopic images of the 
standard macrophage types showed spindle-shaped M1 macrophages and round or 
oval shaped M2 macrophages, where cells treated with the secretome of PSCs 
showed both phenotypes. To further inspect monocyte differentiation, HLA-DR 
expression was measured on the cell surface of the macrophages and found that 
HLA-DR is expressed significantly higher on the cells treated with the PSC 
secretome than those primed with M-CSF and GM-CSF (Figure 14) where no 
significant difference between primed cells with M-CSF and GM-CSF have been 
seen. 
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Figure 12. Representative dot plot and FACS histogram show the purity of isolated CD14+ 
monocytes. At least 1x104 events were collected and analyzed by flow cytometry using CD14-isotype 
as negative control (B, in red). Monocytes composed 93% of total isolated cells (A) as determined by 
CD14 staining (B). 
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Figure 13. Characterization of monocyte differentiation to macrophages. Microscopic images of 
M1 macrophages (LPS+IFN stimulated) exhibiting typical spindle shaped morphology whereas M2 
cells (IL4/10/13 stimulated) have round-shaped cells. Monocytes treated with secretome of 
activated/non-activated PSCs have both M1 and M2 characteristics. All images were taken with 10x 
objective lens. 
 
 
Figure 14. Expression of HLA-DR on the surface of treated macrophages. Monocytes treated with 
M-CSF, GM-CSF and PSC secretome. The secretome significantly increased HLA-DR expression on 
macrophages confirming monocytes differentiation. Data expressed as mean values with the standard 
deviations of three biological replicates, * P<0.05, ****P<0.0001, ns = not significant. 
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10.2.2. Analysis of macrophage polarization surface markers by FACS 
After treating macrophages with the secretome of PSC and PDAC cell lines, the cells 
were harvested, and macrophage polarization markers were analyzed on the surface 
of the cells. Flow cytometry was performed for seven independent experiments 
whereby the analysis revealed the polarization of the macrophages based on the 
expression of M2 surface markers such as scavenger receptor (CD163) and 
mannose receptor (CD206) as well as M1 surface marker, CD86 (Figure 15). The 
histograms are showing the expression of cell surface markers of each treatment 
including the positive control groups; M1 and M2. Moreover, to show the influence of 
different treatments, the mean fluorescence intensity (MFI) of each marker was 
calculated by dividing the geometric mean of the antibody to its isotype control 
(Figure 16).  
The M2 markers (CD163 and CD206) were highly expressed on M2 positive control 
and on macrophages which were treated with the secretome of activated PSC and 
PDAC. As it is assumed, the M1 marker CD86 was expressed higher on the surface 
of M1 positive control as well as on the macrophages which were treated with the 
secretome of non-activated PSC. From the FACS histograms, it could be concluded 
that the secretome of PDAC and the activated PSCs promote macrophages towards 
the M2 phenotype while the non-activated PSCs secretome induced M1 type of 
macrophages which are the physiological proinflammatory phagocytes. 
Nevertheless, to see the differential effect of different PSC secretome on 
macrophage polarization, the data of each experiment was analyzed separately by 
comparing the data of activated PSCs (PSC-TNF) to the non-activated PSC control 
(PSC_Ctrl). The secretome of activated PSCs had significantly enhanced the 
expression of CD163 and CD206 on the macrophages whereas the increased 
expression of CD86 by the secretome of non-activated PSCs was not significant 
(Figure 17). 
Results 
55 
 
 
M1 
CD86 CD163 CD206 
M2 
PSC_TNF 
PSC_Ctrl 
PDAC 
N
o
rm
a
li
z
e
d
 t
o
 m
o
d
e
 
c
o
u
n
t 
0
5
10
15
20
25
M1 M2 PSC_Ctrl PSC_TNF PDAC
M
FI
CD86 CD206 CD163
Figure 16. FACS histograms showing the expression of M1 (CD86) and M2 (CD163 and CD206) 
cell surface markers. Macrophages were treated with the secretome of activated PSC (PSC_TNF), 
non-activated PSC (PSC_Ctrl) and PDAC. M1 and M2, the positive controls, were treated with 
LPS+IFN and IL-4/10/13 respectively. Isotype control of each antibody was used as a negative 
control (dashed line). The data were analyzed using the FlowJo software. 
Figure 15. Mean Fluorescence Intensity (MFI) of CD86, CD163 and CD206 markers expressed 
on macrophages. MFI values were calculated relative to the isotype control of the corresponding 
antibodies. Data of seven independent experiments were shown as mean values with respective 
standard deviations.  
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10.2.3. Analysis of cytokine and chemokines in macrophage at the RNA 
level  
The effect of the PSCs secretome on macrophage polarization was evaluated at the 
RNA level using quantitative real time PCR (qRT-PCR). Cytokines and chemokines 
such as TNF-α, IL-1β, CCL17 and mannose receptor (CD206) were measured in the 
treated macrophages with the secretome of activated PSCs and non-activated PSCs 
(Figure 18). Of note, CD206 was measured again to validate the flow cytometry 
result. It has previously been shown that M1 macrophages express higher TNF-α, IL-
1β whereas CCL17 and CD206 are highly expressed by M2 macrophages [195]. The 
macrophages treated with the secretome of activated PSCs expressed significantly 
higher levels of CD206 and CCL17 (Figure 18 A & B) but lower levels of IL-1β and 
TNF-α (Figure 18 C& D) compared to the macrophages treated with non-activated 
PSC secretome. In accordance with the flow cytometry data, the secretome of non-
activated PSCs significantly increased the levels of M1 markers, IL-1β and TNF-α. 
 
Figure 17. Changes in cell surface marker expression and median fluorescence intensity (MFI) 
values of macrophage markers after treatment with the secretome of activated and non-
activated PSC.  A, FACS Histogram of three independent experiments showing the expression of 
CD86, CD163 and CD206 markers on macrophages treated with activated PSC secretome (Red area) 
and non-activated PSC (dashed line). B, MFI values of CD86, CD163 and CD206 markers expressed 
on macrophages were calculated relative to the isotype negative control. The secretome of activated 
PSC has significantly increased M2 (CD163 and CD206) markers whereas the expression of the M1 
marker (CD86) does not change significantly. Data of seven independent experiments were analyzed 
and presented as median values with the respective standard deviations. * P<0.05, ns=not significant 
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10.2.4. Arginase expression and NO production by the treated 
macrophages 
To further characterize functional changes in macrophages after incubation with the 
conditioned media of PSCs, type-1 arginase (Arg-1) expression and activity as well 
as nitric oxide (NO) production were measured. Arginase expression is associated to 
the M2 type macrophages and it is involved in L-arginine metabolism in the process 
of tissue repairing. In contrast, nitric oxide which is also produced from L-arginine 
metabolism by iNOS enzyme, is associated to the M1 phenotype [123]. Arginase and 
NO were assessed in Raw264.7 mouse macrophages which were treated with 
activated and non-activated PSCs secretome for 48 hours. Arginase activity was 
measured based on urea production whereas arginase expression was measured in 
the cell lysates by western blotting (Figure 19). Arginase activity was significantly 
increased in macrophages which were treated with IL4/13 (positive control) and with 
Figure 18. Real-time PCR analysis of macrophage cytokine and chemokine expression in 
primary macrophages treated with PSCs secretome.  RT-PCR was carried out on representative 
cDNA of each sample. M2 markers CD206 (A), CCL17 (B) and M1 markers, IL-1β (C), TNF-α (D), 
were quantified relative to the non-treated control and normalized to the internal control (GAPDH). 
Data were analyzed using an unpaired t-test. * P<0.05, ** P<0.005, **** P<0.0001. 
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the secretome of activated PSCs in comparison to the treated macrophages with 
non-activated PSC secretome and non-treated control (NT) as in Figure 19 A. Of 
note, the effect of non-activated PSC secretome was not significant. The western blot 
data confirmed that, macrophages treated with the secretome of activated PSC 
promoted the expression of arginase in comparison to the macrophages treated with 
the secretome of non-activated PSC (Figure 19B).  
 
 
On the other hand, expression of iNOS, the enzyme responsible for NO production 
from arginine, couldn’t be detected by western blot although various parameters were 
changed such as concentrations of the antibody, incubation times, washing and 
developing time. (data not shown). Alternatively, NO was measured in the 
conditioned media (CM) of the PSCs and macrophages, as a byproduct of arginine 
metabolism by iNOS. Because CM of PSCs were used in the treatment of 
macrophage, therefore, NO was first measured in the PSC’s CM to be subtracted 
from the NO values of the macrophages afterwards. However, NO production didn’t 
change significantly between the CM of activated and non-activated PSCs (Figure 
20A). But the CM of non-activated PSCs significantly increased the NO production in 
macrophages (Mθ-PSC_Ctrl) when compared to the macrophages which were 
Figure 19. Effect of the PSCs secretome on arginase activity and expression by macrophages. 
Macrophages were treated for 48 h with the secretome of activated PSCs (Mθ-PSC_TNF), non-
activated PSC (Mθ-PSC_Ctrl), IL-4/13 as positive control and no treatment (NT) as negative control. 
A, arginase activity was measured in cell lysates (n=4) and compared to the non-treated control (NT). 
Data were analyzed using two-tailed, unpaired t-test and results were expressed as mean values with 
the standard deviations. B, Western blot indicated the arginase-1 expression in macrophage lysates. 
The relative intensity of each sample was normalized to α-Actinin which serves as the internal control. 
NS= not significant, ** P-value<0.005. 
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treated with the activated PSCs CM (Mθ-PSC_TNF) in both time points (Figure 20B). 
Additionally, a significant difference in NO production could be seen in the 
macrophages which were treated with the CM of non-activated PSCs comparing the 
48 h treatment to the 24 h.  
 
 
 
10.2.5. ROS synthesis in macrophages up on treatment  
ROS are known as PSC activating agents which are contributed to the polarization of 
macrophages into M2 type [80, 196]. Therefore, ROS was measured in the treated 
macrophages with the PSCs secretome. As it is shown in Figure 21, macrophages 
treated with the secretome of activated PSCs (Mθ-PSC_TNF) produce significantly 
lower ROS in both 24 h and 48 h treatments compared to the macrophages treated 
with the secretome of non-activated PSCs (Mθ-PSC_TNF). Remarkably, ROS 
production decreased in the 48 h treatment compared to the 24 h of both treatments. 
This suggests the possibility of M1 polarization by the secretome of non-activated 
PSCs because it is already known that NO and ROS are highly produced by the pro-
inflammatory macrophages [110]. 
Figure 20. Nitric oxide (NO) production by macrophages and PSCs. A, NO was measured in the 
CM of PSCs before they were used in macrophage treatment using Griess method. NO production 
was not changing significantly between the stimulated PSCs and the control. B, macrophages treated 
with the non-activated PSCs CM (Mθ PSC_Ctrl) produce significantly higher NO after 24 and 48 h 
treatment when compared to the macrophages treated with the conditioned medium of activated PSC 
(Mθ PSC_TNF). Data were analyzed using a two-tailed, unpaired t-test and results were expressed as 
mean value and respective standard deviations. ***P<0.005, ****P<0.0001, # significant comparing 
24h to 48 h, ns=not significant 
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10.2.6. Role of PSC-educated macrophages in PDAC cell proliferation 
The influence of macrophage CM has been studied in different tumors [197, 198], 
however, to our knowledge, role of macrophages which have been incubated with the 
PSC’s secretome on the proliferation of cancer cells is not studied yet. We aimed to 
investigate the paracrine signaling between incubated macrophages with PSC’s 
secretome and pancreatic cancer cells. Accordingly, Panc-1 cells were treated with 
the secretome of the pre-treated macrophages with PSC secretome for 24 and 48 h. 
Macrophages which were incubated with the secretome of activated PSCs have 
significantly increased Panc-1 proliferation at both time points compared to those 
treated with the secretome of non-activated PSCs (Figure 22 A&B). There is a 
significant difference between the non-treated control which is incubated in serum 
free medium (SFM) and the positive control (10% FBS) treatment. 
 
 
 
 
 
 
 
Figure 21. Reactive oxygen species (ROS) production by macrophages. ROS were measured in 
the macrophages treated with the secretome of PSCs after 24 and 48 h using 2´,7´-dichlorofluorescein 
diacetate (DCFH-DA). Macrophages treated with activated PSC’s secretome (Mθ PSC_TNF) produce 
significantly lower ROS compared to the those treated with non-activated PSC (Mθ PSC_Ctrl). Data 
were analyzed using a two-tailed, unpaired t-test and results were expressed as mean values with the 
standard deviation. *P<0.05, ****P<0.0005. 
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10.3. Influence of IL-6 on macrophage polarization  
IL-6 is a proinflammatory factor which is significantly upregulated in the secretome of 
activated PSCs (Figure 8D and Table 2). It has been also shown that IL-6 is 
changing the differentiation of monocytes  from dendritic cells to macrophages [199]. 
However, influence of IL-6 on the expression of surface markers during macrophage 
polarization, and after polarization is not known yet. 
 
10.3.1. Pre-polarization effect of IL-6 
First, IL-6 was used with the standard stimuli of macrophage polarization, so that 
monocytes were stimulated with LPS/IFN and IL-6 to polarize into M1 macrophages 
whereas IL4 and IL-6 were used to induce M2 polarization. After three days 
incubation, macrophage surface markers (CD80 and CD206) were analyzed by flow 
cytometry and overlaid as histograms to see the differences (Figure 23). Surprisingly, 
IL-6 didn’t show a remarkable effect on the M1 markers CD80 (Figure 23 A) whereas 
the expression of M2 marker, CD206 was decreased by IL-6 compared to the 
controls, (Figure 23 B).  
  
 
Figure 22. Regulation of pancreatic ductal adenocarcinoma cell (Panc-1) proliferation by the 
secretome of pre-treated macrophages with the PSCs secretome.  Panc-1 cells were treated for 
24 h (A) and 48 h (B) with the secretome of macrophages which were incubated with the PSCs 
secretome. Relative cellular proliferation was determined using the fluorescent resazurin dye. Data 
were analyzed using a two tailed, unpaired t-test and results of five biological replicates were 
expressed as mean values with the standard deviations. ***P<0.0005, ****P<0.0001, # significant 
compared to SFM, ns=not significant. 
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10.3.2. Effect of IL-6 post-polarization 
The second strategy was to evaluate the impact of IL-6 particularly on polarized 
macrophages. Accordingly, macrophages were polarized to M1 and M2 phenotypes 
using a standard procedure of LPS/IFNγ and IL4/13 stimulation respectively. After 
four days of polarization, M1 and M2 macrophages were subsequently, either treated 
only with recombinant IL-6 or kept non-treated as controls for 48 h. The expression of 
surface markers on both macrophage types were analyzed with FACS. The FACS 
histograms (Figure 24) demonstrate that, in comparison to the controls, IL-6 
increased the expression of CD206 on both M1 and M2 polarized macrophages 
(Figure 24 C & D). Of note, IL-6 didn’t show any visible effect on the expression of 
CD80 on M1 and M2 macrophages (Figure 24 A & B). The effect of IL-6 on 
macrophages at two different stages of polarization are contradictory where IL-6 
decreased the M2 marker CD206 when used during polarization but in contrast, it 
increases CD206 expression on both M1 and M2 polarized macrophages.  
Figure 23. Effect of IL-6 in stimulating macrophage’s surface marker expression. FACS 
histograms are showing the difference in surface marker expression between macrophages stimulated 
with IL-6 (orange dashed line) and the controls of both M1 (blue line-A) and M2 (black line-B). IL-6 
was used with the standard polarization stimuli of M1 (LPS/IFN) and M2 (IL-4) compared to the 
controls. 
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Functional effects of IL-6 on macrophages 
We have shown that PSC’s secretome increases arginase activity and decreases NO 
production in macrophages. In the secretome of activated PSCs IL-6 is upregulated 
and predicted to activate macrophages (Figure 8 D, Table 2). Therefore, we have 
further evaluated the influence of IL-6 on arginase activity and NO production in 
macrophages. Arginase activity and NO were measured in M1, M2 as well as in the 
macrophages which were treated with IL-6 and analyzed in comparison to the control 
(M0). IL-6 had no significant effect neither on arginase activity (Figure 25 A) nor on 
NO synthesis (Figure 25 B) compared to the non-treated macrophages (M0). As it 
was expected, the NO synthesis and arginase enzyme activity were significantly 
increased by the positive controls, M1 and M2, respectively. Also, M2 macrophages 
Figure 24. Effect of IL-6 on the expression of macrophage’s surface markers after polarization. 
Macrophages which were previously polarized to M1 (A & C) and M2 (B & D) phenotypes were 
exposed to recombinant IL-6. Histograms showing the change in the expression of M1 (CD80) and M2 
(CD206) surface markers where the controls (dashed line) were compared to the IL-6 treated 
macrophages (normal line). FACS data were analyzed and histograms were made with FlowJo. This 
experiment was performed together with Justus Weber. 
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produced significantly lower NO compared to the non-treated control. Thus, IL-6 in 
the secretome of activated PSCs, for example, couldn’t be attributed to the increase 
of arginase expression and decrease of NO synthesis. 
 
 
 
10.3.3. Expression profiling of macrophages treated with PSC secretome 
In order to investigate the impact of secreted proteins by PSCs on macrophages 
function, macrophages were treated with the secretome of PSCs for four days. The 
proteome and secretome changes of treated macrophages were analyzed by 
antibody microarray and ingenuity pathway analysis (IPA). 
Macrophage’s secretome characterization 
The secretome of treated macrophages with activated and non-activated PSCs was 
collected and analyzed by antibody microarrays. The antibody microarray data was 
analyzed by Chipster to see the clustering of the samples. The dendrogram shows a 
clear separation of the groups indicating that the PSC secretome affects the 
macrophages secretome profiles (Figure 26 A). However, 689 proteins were 
differentially regulated between the treated macrophages (data not shown). The IPA 
analysis was performed and predicted that functions associated with cellular 
movement, development, cellular growth and proliferation, cell to cell signaling and 
inflammatory response were affected (Figure 26 B). Remarkably, a clear difference 
Figure 25. Influence of IL-6 on arginase activity and nitric oxide synthesis in macrophages. 
Arginase activity (A) and nitric oxide production (B) were measured in non-treated macrophages (M0), 
M1 and M2 polarized macrophages as well as in macrophages treated with IL-6 (+IL-6). No significant 
changes in arginase activity and NO are noticeable. Data were analyzed using a two tailed, unpaired t-
test and represented as mean values with the standard deviations. * P<0.5, ** P 0.005, **** P<0.0001, 
ns – not significant. Compared to M0. 
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can be seen in cellular movement and cell to cell signaling and interaction between 
the treatments. Furthermore, the IPA downstream analysis of top functions resulted 
in the increase and decrease of functions that are associated to immune cells, for 
example (Table 4.). Interestingly, activation and migration of immune cells were 
predicted to increase whereas phagocytosis is predicted to decrease. Taken together 
the predicted data by IPA indicated that, the secretome of activated PSCs mainly 
affect the proteins that are involved in inflammation and cell signaling. This supports 
the experimental data which showed that the PSCs secretome changed the 
polarization of macrophages and increased cancer cell proliferation. 
 
Table 4. Downstream effect analysis for the secretome expression profiling data of 
macrophages after treatment with PSC secretome. Listed are the most relevant diseases and 
functions, their overlap p-values, the predicted activation states with activation z-scores higher than 2 
and the number (#) of molecules that are associated with each disease or function. 
Diseases or Functions Annotation p-Value 
Predicted  
Activation State 
Activation  
z-score 
# of 
Molecules 
Morbidity or mortality 5.29E-66 Increased 4.297 239 
Organismal death 5.7E-65 Increased 4.084 236 
Function of leukocytes 1.9E-43 Increased 2.971 86 
Activation of phagocytes 4.86E-37 Increased 2.559 70 
Non-traumatic arthropathy 1.59E-44 Increased 2.535 118 
Migration of phagocytes 8.66E-46 Increased 2.508 69 
Function of blood cells 2.56E-51 Increased 2.442 99 
T cell migration 1.74E-40 Increased 2.441 63 
Activation of myeloid cells 1.03E-36 Increased 2.385 67 
Proliferation of prostate cancer cell lines 7.63E-27 Increased 2.322 55 
Rheumatic Disease 1.31E-56 Increased 2.239 155 
Activation of leukocytes 1.51E-62 Increased 2.203 125 
Cell movement of T lymphocytes 4.36E-34 Increased 2.154 54 
Activation of blood cells 3.42E-66 Increased 2.053 133 
Migration of lymphatic system cells 1.92E-53 Increased 2.013 87 
Migration of antigen presenting cells 9.61E-28 Increased 2.008 41 
Activation of T lymphocytes 2.18E-53 Increased 2.001 84 
Diseases or Functions Annotation p-Value 
Predicted  
Activation State 
Activation  
z-score 
# of 
Molecules 
Differentiation of epithelial tissue 1.4E-27 Decreased -2.012 62 
Apoptosis of fibroblast cell lines 1.03E-30 Decreased -2.049 59 
Progression of tumor 3.4E-38 Decreased -2.137 61 
Viral Infection 4.64E-57 Decreased -2.174 180 
Infection by RNA virus 1.36E-28 Decreased -2.261 98 
Phagocytosis of cells 1.11E-30 Decreased -2.27 56 
Survival of organism 4.68E-56 Decreased -2.282 123 
Phagocytosis 5.8E-30 Decreased -2.356 58 
Progression of malignant tumor 1.51E-30 Decreased -2.384 45 
Transport of molecule 8.68E-28 Decreased -2.396 136 
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Macrophage’s proteome characterization 
The cellular proteome of treated macrophages was analyzed by antibody microarrays 
as reported before. However, the downstream effect analysis by IPA resulted in a list 
of interesting diseases and functions (Table 5) in which invasion and movement of 
tumor cells were predicted to increase. This however, supports the increased PDAC 
proliferation by pre-exposed macrophages to PSCs secretome (Figure 22) and is 
consistent with the fact that tumor educated macrophages promote pancreatic cancer 
[200]. Similar to the secretome analysis, phagocytosis is predicted to decrease in the 
cellular proteome analysis under the effect of PSC secretome. Most interestingly, 
most of the predicted functions are associated with the functional changes in immune 
cells which alternatively promote cancer progression [130].  
A comparison analysis by IPA has shown that cell cycle regulation is highly 
upregulated by macrophages upon treatment (Figure 27 A). The cell cycle 
progression is highly upregulated in macrophages under the effect of non-activated 
PSCs secretome (Figure 27 B). Still, there is no clear difference in the upstream 
regulators between the two groups (Figure 27 C). Nevertheless, analyzing the 
significantly regulated molecules which were involved in invasion of tumor cells 
showed that most of the molecules are upregulated in the proteome of treated 
macrophages and predicted to increase tumor invasion (Figure 28). Taken together, 
these data suggest that PSCs secretome enhance macrophages polarization into M2 
Figure 26. Effect of PSC secretome on macrophage (THP-1) secretome profile and function. A, 
the dendrogram shows the clustering of the macrophages treated with activated PSC secretome 
(PSC_TNF) and non-activated (PSC_Ctrl). B, Heatmaps of predicted phenotypes with the molecular 
and cellular functions. Each rectangle represents one function whereas the size associates with the 
number of involved genes. The color indicates the predicted activation state (Orange = activation, Blue 
= attenuation). 
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type and suppress immune cells functions leading to a decreased immune response 
and consequently increased tumor progression. 
 
 
Table 5. Downstream effect analysis for the proteome expression profiling data of 
macrophages after treatment with PSC secretome. Listed are the most relevant diseases and 
functions, their overlap p-values, the predicted activation states with activation z-scores and the 
number (#) of molecules that are associated with each disease or function and were regulated in the 
analysis. 
 
 
 
 
 
 
 
 
Diseases or Functions  
Annotation 
p-Value Predicted  
Activation State 
Activation z-
score 
# 
Molecules 
Invasion of tumor cells 2.22E-27 Increased 2.648 44 
Invasion of tumor 1.27E-35 Increased 2.64 59 
Cell movement of carcinoma cell lines 5.31E-38 Increased 2.167 62 
Transactivation 2.73E-31 Increased 2.042 88 
Fibrosis 3.01E-40 Increased 2.006 100 
     
Diseases or Functions  
Annotation 
p-Value Predicted  
Activation State 
Activation z-
score 
# 
Molecules 
Response of phagocytes 3.54E-31 Decreased -2.009 55 
Phagocytosis 5.07E-33 Decreased -2.079 67 
Response of myeloid cells 2.02E-31 Decreased -2.119 55 
Adhesion of granulocytes 2.98E-31 Decreased -2.141 40 
Binding of myeloid cells 5.41E-39 Decreased -2.15 60 
Binding of granulocytes 2.78E-32 Decreased -2.195 44 
Immune response of cells 1.34E-54 Decreased -2.227 118 
Interaction of leukocytes 1.34E-53 Decreased -2.229 96 
Immune response of phagocytes 2.27E-29 Decreased -2.256 51 
Adhesion of myeloid cells 3.79E-32 Decreased -2.288 47 
Binding of leukocytes 3.71E-53 Decreased -2.31 95 
Interaction of blood cells 1.42E-55 Decreased -2.324 103 
Immune response of leukocytes 6.97E-36 Decreased -2.352 70 
Binding of blood cells 4.79E-55 Decreased -2.411 102 
Phagocytosis of cells 2.4E-32 Decreased -2.57 63 
Adhesion of immune cells 1.02E-46 Decreased -2.602 85 
Adhesion of blood cells 1.53E-48 Decreased -2.865 90 
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Figure 27. Ingenuity Pathway Analysis for the effects of PSC secretome on THP-1 
macrophages at the proteome level.  A comparison analysis was performed for the cellular 
proteome of macrophages treated with the activated (PSC_TNF) and non-activated (PSC_Ctrl) PSC 
secretome. The color grades indicate the predicted activation state (Orange = Activation, Blue = 
Attenuation). Comparison analysis was performed for the proteome and canonical pathways (A), 
diseases and functions (B) and upstream regulators (C) are showing the differences. 
Figure 28. Molecules in the macrophages affecting the invasion of tumor cells. Network was 
generated by IPA representing proteins that are related to invasion of tumor cells and whose levels 
were significantly different between the proteome of treated macrophages. Lines between the proteins 
show the known interactions. The orange arrows mean activation, blue arrows inhibition; yellow 
arrows indicate that the regulation observed is inconsistent with predictions; grey arrows indicate lack 
of existing data to formulate any prediction. 
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10.4. Application of cancer cell secretome in diagnosis of pancreatic 
ductal adenocarcinoma  
Since the PSCs secretome had shown interesting roles in cell to cell communication 
as explained in the previous parts, it was interesting to see which proteins could act 
as biomarkers for disease diagnosis. Hence, we have collected and analyzed the 
secretome of a panel of pancreatic tumor and non-tumorous cell lines using antibody 
microarrays. Based on the secretome results, we studied sera of PDAC patients, 
chronic pancreatitis (CP) and sera from healthy donors for the establishment of a set 
of defined biomarkers. The serum samples of two independent training and test sets 
of patients were analyzed and studied on two distinct formats of antibody 
microarrays, respectively. The potential of translating the identified marker signature 
into a clinical format was demonstrated by subsequent validation with commercial 
ELISA kits.  
10.4.1. Secretome and array quality analysis  
The cellular proteome of the pancreatic cancer cell lines which were used in the 
secretome analysis have been studied before using the same antibody microarray 
setup [185]. However, secretome of six primary pancreatic cancer cell lines and 
human fibroblasts were added to the study (Table 6). The established pancreatic 
cancer cell lines were isolated from different tumor origins of male and female 
patients such as, primary tumor, liver or lymph node metastasis and ascites that had 
different grades of differentiation. To analyze the secretome of each cell line, 
secretome samples were concentrated and labeled with fluorescent dye then 
incubated with the common proteome reference which were prepared from the pool 
of cellular proteome as reported previously [185]. The secretome samples were then 
analyzed using antibody arrays targeting 735 proteins as described in the methods. 
“The results without normalization had similar data quality in a way that the signal to 
noise ratio (SNR) larger than two times the standard deviation of the average 
background signal at this location was higher than 93% for the common reference 
but varied around 80% for the incubations of the secretome (Figure 29 A). For 
individual proteins, signal-to-noise ratios as high as 100 were observed; the mean 
across all proteins with signals above background was 4.38 (±7.68). Data 
normalization yielded highly comparable results (Figure 29 B). The intra- and inter-
array coefficients of variation across a large number of microarray production batches 
ranged between 13% and 20%.”[180] 
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Table 6. Characteristic and clinical features of cell lines used in secretome collection. 
Description of established pancreatic cancer cell lines. 
Cell line 
Patient 
gender 
Cell source Histology Grade 
Age 
(years) 
A818-1 Female Ascites 
Moderately differentiated, ductal 
adenocarcinoma 
G2 75 
AsPC-1 Female Ascites 
Well-moderately differentiated, ductal 
adenocarcinoma 
G2 62 
BxPC-3 Female Primary tumor 
Moderately differentiated, ductal 
adenocarcinoma 
G2 61 
CFPAC-1 Male 
Liver 
metastasis 
Well differentiated, ductal adenocarcinoma; 
cystic fibrosis 
- 26 
Colo357 - 
Lymph node 
metastasis 
Well differentiated, ductal adenocarcinoma G2 - 
MIA PaCa-2 Male Primary tumor 
Post-moderately differentiated, ductal 
carcinoma 
G3 65 
PaCa-44 Female Primary tumor 
Moderately differentiated, ductal 
adenocarcinoma 
G2 44 
PANC-1 Male Primary tumor 
Poorly differentiated, ductal epithelioid 
carcinoma 
G3 56 
Pt45P1 - Primary tumor 
Moderately differentiated, ductal 
adenocarcinoma 
G3 - 
SK-PC-1 Male Primary tumor Well differentiated, ductal carcinoma - - 
Clinical features of the primary pancreatic cancer cell lines. 
Cell line 
Patient 
gender 
Tumor 
localization 
Histology 
Classification 
Postoperativ
e survival 
(days) 
Patient 
status 
T N M G 
 
PacaDD119 Male Pancreas head 
Poorly differentiated, 
ductal 
adenocarcinoma 
3 1 0 3 445 Dead 
PacaDD137 Female Pancreas head 
Moderately 
differentiated, ductal 
adenocarcinoma 
2 0 0 2 478 Alive 
PacaDD159 Male Pancreas tail 
Moderately 
differentiated, ductal 
adenocarcinoma 
3 0 0 2 169 Dead 
PacaDD135 Female 
Liver 
metastasis 
Moderate-poorly 
differentiated, ductal 
adenocarcinoma 
(partially mucinous) 
- - Hep 2 66 Dead 
PacaDD161 Female 
Liver 
metastasis 
Poorly differentiated, 
adenocarcinoma 
- - Hep 3 x Dead 
PacaDD183 Female Pancreas head 
Moderate 
differentiated, ductal 
adenocarcinoma 
- - - 2 55 Dead 
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Figure 29. Quality assessment of microarray analyses. (A) The median percentage of microarray 
antibodies is shown that exhibited a signal that was significantly above background. The black bars 
represent the results with the intracellular proteins used as common reference; the grey bars stand for 
the secretome samples. The order of the cells was defined by the amount of protein that was obtained 
from the secretome, from relatively high (left) to low amounts (right). As can be seen, there was no 
apparent influence of the protein preparation yield. (B) A box plot representation is shown of all signal 
intensities of the secretome samples normalized to the pool reference. 
 
10.4.2. Cancer cell secretome characterization and comparison  
The secretome of the cancer cell lines and fibroblasts were profiled with antibody 
microarrays and analyzed by Chipster software package. Comparing the cancer cell 
lines secretome to the fibroblasts resulted in 112 differentially abundant proteins 
which were similarly expressed at least in 14 cancer cell lines (online suppl. Table. 2 
[180]). Functional data analysis was performed with the IPA software which revealed 
that most of the proteins are involved in functional categories of cell death and 
survival, inflammatory response, decreased apoptosis and cell death as well as 
increase in organismal death and cancer (Table 7). “This result indicates a potential 
role of secreted proteins as anti-apoptotic factors that could be involved in the control 
of the maintenance and survival of pancreatic tumor cells and reflects the bad 
Results 
72 
 
prognosis associated with the tumor. In addition, the secretome profiles predict an 
influence of PDAC tumor cells on regulating immune cells and their quantity within 
the tumor, suggesting that tumor cells could control the trafficking of immune cells, 
such as phagocytes, monocytes and neutrophils, into the tumor microenvironment” 
[180]. However, in order to verify the predicted role of pancreatic cancer cell 
secretome by IPA analysis, macrophages polarization was evaluated under the effect 
of PDAC secretome. Remarkably, the PDAC secretome promotes macrophages 
polarization towards the anti-inflammatory M2 type (Figure 15 & Figure 16). 
“Moreover, there was not a big difference between the secretome of established and 
primary pancreatic cancer cell lines. That means, the origin of tumor, tumor location 
and the grade did not make a noticeable change in the secretome data. However, 
this is inconsistent with the proteomic data of the same cell lines where a significant 
variation has been seen between them [185]. Besides, some of the proteins that 
were regulated in the tumor cell secretome had been reported to be present in body 
fluids, such as saliva, cerebrospinal fluid, tears, blood or urine” [180]. 
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Table 7. List of the most frequently predicted functions associated with the secretome of 
pancreatic cancer cell lines. The prediction z-score was calculated within IPA software. The 
complete list can be found as supplemental information online (Suppl. Tab. 3). [180] 
Function 
annotation 
Predicted 
activation 
state 
Prediction 
(z-score) 
p-Value Proteins 
Number 
of 
proteins 
Cell death of 
pancreatic 
cancer cell 
lines 
Decreased -2.568 4.59 E-07 
ALB, CXCL8, DDIT3, FN1, 
MTOR, RPS19, SPP1, 
TGFB1 
8 
Apoptosis of 
pancreatic 
cancer cell 
lines 
Decreased -2.365 2.27 E-06 
ALB, CXCL8, DDIT3, FN1, 
MTOR, RPS19, TGFB1 
7 
Quantity of 
phagocytes 
Increased +2.049 3.53 E-12 
BCL2A1, CNN2, CXCL8, 
DCN, FABP1, FASTK, FPR1, 
GJA1, ID1, IL10, IL1A, IL2, 
S100A8, SELE, SELL, SPP1, 
TGFB1, TGFBR2, TIA1, 
VCAM1 
20 
Quantity of 
neutrophils 
Increased +2.156 1.23 E-10 
CNN2, DCN, FASTK, FPR1, 
GJA1, ID1, IL10, IL1A, 
S100A8, SELE, SELL, 
TGFB1, TIA1, VCAM1, 
AKR1C3, APC, ATP6AP1, 
14 
Organismal 
death 
Increased +2.174 1.49 E-15 
BCL2A1, BGN, CTTN, 
CXCL8, DAB2, DCN, DDX17, 
EIF2AK4, EPHB3, FN1, FOS, 
GAS1, GJA1, GPM6B, 
HNRNPC, HSP90B1, ID1, 
IL10, IL2, IMPDH2, KLF4, 
LAMTOR1, MAPK3, MLH1, 
MME, MMP2, MTOR, 
NCOR2, NUSAP1, PAX2, 
POU2F1, PVRL1, RPS19, 
RPSA, S100A8, SELE, 
SERPINB5, SLC19A1, 
SPINT2, SPP1, TCEA1, 
TGFB1, TGFBR2, TIA1, 
TIE1, TJP2, TOP2A, TPT1, 
UBC, VCAM1, ZBTB17 
54 
Quantity of 
monocytes 
Increased +2.256 1.85 E-08 
CNN2, CXCL8, GJA1, ID1, 
IL10, IL1A, SELE, SELL, 
VCAM1 
9 
 
10.4.3. Comparison of secretome to the related intracellular proteome 
Intracellular proteome of the same PDAC cell lines have been studied previously with 
the same antibody microarrays [185] however, to know the regulation of different 
proteins, a comparison was necessary. “Comparing the profiles, the majority of 
changes in abundance were unique to either the intracellular proteome or the 
secretome. Only 17 proteins were similarly regulated between the two sample types 
(Figure 30). This represents 15% (17/112) of the secretome-specific and 13% 
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(17/132) of the intracellular proteome variations, or some 2% (17/735) of all studied 
proteins. Most of the 17 proteins are actually associated with extracellular functions, 
according to gene ontology (GO) terms, or are sheded components of the plasma 
membrane. All exhibited a substantially larger abundance variation in the secretome 
than intracellularly. For the large majority of proteins, however, the expression 
patterns were different in secretome and intracellular proteome. For example, most 
cytokines were found up-regulated in the secretome and down-regulated 
intracellularly, while the opposite was observed for nuclear proteins like RPS19, NCL 
and BRPF3” [180].  
 
 
Figure 30. Proteins that are commonly regulated in secretome and intracellular proteome of the 
tumor cells. The proteins are listed, which exhibited similar regulation in both secretome and 
proteome analyses of the established pancreatic cancer cell lines in comparison to non-tumor cells. 
The bar sizes indicate the relative degree of regulation. 
 
10.4.4. Protein variations in patient serum samples  
“To investigate the impact of secretome data on the quality of a patient diagnosis 
based on serum protein data, serum samples from patients were studied. Two 
independent sample groups, a training and test set, were used in this analysis. The 
training set consisted of sera from 47 PDAC patients, 18 people with chronic 
pancreatitis (CP) and 27 age and sex-matched healthy individuals. The test set was 
composed of 25, 25 and 22 serum samples, respectively. The characteristics of the 
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patients and donors are summarized in Table 8. Two distinct antibody microarrays 
were used for the analysis as it is described in the method. However, several 
antibodies of the smaller microarray were missing on the larger array as supplies had 
run out and could not be replaced” [180]. 
 
 
Table 8. Characteristics of healthy donors and patients from whom serum samples were 
collected. 
Healthy donors 
Age: range (average) 
Sample set 1:  39-71 (52) 
Sample set 2:  35-74 (55) 
Gender: male/female 
Sample set 1:  0.60 
Sample set 2:  0.62 
CP patients 
Age: range (average) 
Sample set 1:  25-76 (44) 
Sample set 2:  24-78 (51) 
Gender: male/female 
Sample set 1:  0.70 
Sample set 2:  0.85 
PDAC patients 
Age: range (average) 
Sample set 1:  39-74 (58) 
Sample set 2:  38-81 (61) 
Gender: male/female 
Sample set 1:  0.66 
Sample set 2:  0.67 
Tumour localisation % of cases 
Pancreas head 55 
Pancreas body 14 
Pancreas tail 3 
Papilla vateri 10 
Multiple 18 
Grading % of cases 
G2 48 
G3 34 
unknown 18 
R classification % of cases 
R0 55 
R1 38 
R2 3 
 
“Looking at the individual diagnostic accuracy of the 189 proteins that were found to 
be differentially abundant in serum of PDAC patients and healthy donors (online 
suppl. Tabs. 5 and 6  [180]), they differed in their ability to discriminate between the 
two groups as indicated by their individual AUC values. In the training set, rather 
good accuracy values could be determined for some of the proteins (Figure 31 A). 
When controlling these performances in the test set, however, none exhibited an 
overall accuracy that would be sufficient individually (Figure 31 B)” [180].  
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Figure 31. AUC values of the 189 individual serum markers. Analysis by Receiver Operating 
Characteristic (ROC) curves was performed for all identified serum protein markers individually. Panel 
A shows the result calculated from the training set; the respective AUC values are shown, ranging 
from 55.2% to 96.0%. In panel B, the AUC values are shown as calculated for the individual marker 
molecules in the test set. For presentation, the order of the markers along the x-axis was kept as in 
panel A, highlighting the limited degree of reproducibility for individual markers. 
 
 
“Out of the 112 proteins found to vary in the secretome of tumor cells, only 8 proteins 
were similarly regulated in serum samples of PDAC patients, but not exhibiting 
different abundance in CP sera (Figure 32). In all cases, the variation was 
substantially bigger in the secretome than in the serum. Since it is likely that a 
tumor’s secretome gets diluted and in part obscured by the proteins that are secreted 
by cells in other organs and tissues, such a difference is expected. The expression of 
most proteins was either unchanged in one or both sample types or varied even 
inversely in secretome and serum” [180].  
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Figure 32. Proteins that were similarly regulated in both tumor cell secretome and PDAC 
patient sera. Out of the 112 differentially expressed proteins in the tumor cell secretome compared to 
the non-tumorous cells, only 8 were similarly regulated in the serum. The red and green bars indicate 
the degree of regulation in secretome and PDAC serum, respectively. 
 
10.4.5. Serum-based diagnostics 
“The 8 proteins that similarly varied in abundance in PDAC sera and in tumor cell 
secretome – EPHB3, FGF1, ID1, IL2, IL10, IMPDH2, SELL, VCAM1 – did not exhibit 
a superior performance as markers individually (Figure 31). When applied as a 
signature for PDAC diagnosis, however, a Receiver Operating Characteristic (ROC) 
curve analysis yielded an accuracy – expressed as area under the curve (AUC) value 
– of 95.1% for distinguishing PDAC from healthy (Figure 33 A). For comparison, the 
best performing panel of 8 marker molecules, which were differentially abundant in 
sera but not in the secretome, was selected based on the training set. Applied to the 
test set, they produced an AUC value of 84.2% (Figure 33 B). Even applying more 
than 8 of the proteins that showed variation in serum abundance only, no better 
distinction of sera from cancer and healthy patients could be achieved. This 
documents that the information content of the signature based on molecules that 
varied in both secretome and serum is significantly higher than that derived from 
serum-only markers” [180]. 
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Figure 33. Diagnostic potential of the protein signatures in serum. (A) A Receiver Operating 
Characteristic (ROC) curves was calculated for the signature of 8 proteins that exhibited shared 
expression changes in the analyses of PDAC serum and secretome, yielding an AUC value of 95.1%. 
The protein names are shown. (B) In comparison, the ROC curve is presented for the best performing 
panel of 8 proteins that differed in abundance in the serum only; AUC is 84.2%. The relevant proteins 
are listed. 
 
“The 8 markers shared between PDAC cell secretome and PDAC patient sera were 
not able to separate PDAC from CP sera, however. In this context, they performed 
basically identical to the best serum-only marker signature with AUC values of 71.2% 
and 72.2%, respectively (Figure 34). For discriminating PDAC from CP sera, the best 
8 common proteins regulated similarly between PDAC and CP yielded AUC values of 
72.2% (Figure 34 B) whereas the most informative signature was made up of 25 
proteins, yielding in a ROC analysis an AUC value of 97.1% (Figure 35)” [180]. 
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Figure 35. Discrimination of sera from PDAC and CP patients. A ROC curve was calculated for the 
best performing serum proteins that distinguish PDAC from CP sera. AUC is 97.1%. The names of the 
25 proteins are listed at the right margin. 
 
 
 
A B 
Figure 34. Diagnostic potential of PDAC and CP serum markers only. (A) Receiver Operating 
Characteristic (ROC) curves was calculated for the best 8 proteins of PDAC alone discriminating 
PDAC from healthy that yielded an AUC value of 71.2%. (B) Common regulated proteins between 
PDAC and CP sera with the similar expression yielded an AUC value of 72.2%. The relevant proteins 
are listed in the right side. 
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10.4.6. Validation by ELISA 
“Complex antibody microarrays like the ones used here are unlikely to be utilized in 
clinical routine. An analysis would produce information that is not required for 
diagnosis. Also, in terms of robustness, other methods are superior and already 
established in a clinical setting. Therefore, we confirmed our results not just by 
applying a scheme of independent training and test samples but used commercial 
ELISA kits for IL2, ID1, and IL10 in addition. The antibodies of the three ELISA kits 
were different from the molecules on the microarray used to define the diagnostic 
signature. IL2, ID1, and IL10 were selected at random from the eight proteins that 
define the signature. An analysis of all eight was not possible, since the amount of 
serum was limiting. While a protein amount equivalent to about two microliters of 
serum is sufficient for a microarray analysis that studies as many antigens as there 
are antibodies on the microarray, the protein content of 50 µl to 150 µl serum was 
required for each individual ELISA. In total, we analyzed 25 and 21 sera from PDAC 
and healthy control samples, respectively. In agreement with the microarray data, 
both ID1 and IL2 were found significantly lower in PDAC sera as compared to healthy 
control samples and IL10 was present at a significantly higher level (all three with p < 
0.0001) (Figure 36)” [180].  
 
 
 
 
 
 
Figure 36. ELISA validation of identified marker proteins. The protein content was analyzed of 25 
and 21 sera, respectively, isolated from PDAC patients and healthy blood donors. Proteins IL2, ID1, 
and IL10 were studied with commercially available assays. Data were analyzed by GraphPad Prism 
and all markers showed a highly significant degree of variation of abundance. ****P-value<0.0001 
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11. Discussion 
11.1. PSC activation, validation and secretome characterization 
11.1.1. Activation of PSC with TNF-α  
Under the pathological conditions such as pancreatic cancer, the activation of PSCs 
is one of the earliest cellular events that occurs by the different factors such as 
oxidative stress [201], pressure [80], high glucose [202] and proinflammatory factors 
[181]. PSCs even stay activated in vivo after chemoradiation [193]. Activated PSCs 
highly express alpha-smooth muscle actin (α-SMA) and release extracellular matrix 
(ECM) proteins such as collagen [71], metalloproteinases [77] and fibronectin [192]. 
In the present study, the activation of PSCs by TNF-α is confirmed by the increase in 
α-SMA and fibronectin expression. In normal tissues, activated PSCs undergo cell 
apoptosis soon after healing is complete [203] while, during fibrotic diseases, PSCs 
remain activated and highly proliferative leading to the expansion of the ECM and 
induce stromal reaction [71]. The persistent activation of PSCs is involved in the 
development of tumor and metastasis as well as it contributes to inflammatory 
cytokine signaling [71, 94]. Therefore, identifying the secreted proteins of the 
activated PSCs could lead to a better understanding of the functional molecules in 
the tumor microenvironment. 
11.1.2. Characterization and validation of PSC secretome  
The analysis of PSCs secretome using antibody microarrays demonstrated that in 
the secretome of activated PSCs most of the proteins are secreted or are part of the 
plasma membrane. VEGF, ICAM-1, MMP-10, 11,12 and 14 are highly upregulated, 
which are important in the tumor microenvironment. VEGF, for example, promotes 
angiogenesis and activates various signal transduction pathways which subsequently 
leads to the secretion of matrix metalloproteinases (MMPs) [204]. MMPs then 
facilitate the degradation of the ECM leading to the tumor invasion [205] in addition, 
MMP10 is increasing macrophage migration and invasion [206]. Moreover, 
expression of ICAM-1 by activated PSCs mediate the transmigration of leukocytes to 
the site of tissue injury [207].  Our results are in agreement with the findings of Wehr 
et al. who profiled the secretome of PSCs but without activation [208] nevertheless, 
the study plan, experimental design and analysis technique are different. The number 
of proteins identified in their study is higher due to the limited number of antibodies 
on the arrays we used. Still, FN-1, MSN, SERPINE, IGFBP1, for example, are 
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similarly upregulated whereas ANXA2 and CLUSTERIN are in contrast 
downregulated in our study. There are some important proteins which were not 
identified in their study such as IL-2, IL-4, IL-6 and MMPs-10, 11, 12 and 14. Despite 
these variations due to the stimulation of the PSCs with TNF-α, we validated the 
secretome of PSCs using western blot and ELISA.  
The western blot analysis and ELISA confirmed that activated PSCs secreted higher 
amount of IL-6, IL-4, IL-1β, FGF-1, SERPINE, FN-1 and collagen compared to the 
non-activated PSCs. These proteins participate in the cell signaling and promote 
PSC activation, fibrosis, cancer cell proliferation, immunosuppression and 
angiogenesis [126]. IL-6, for example, is a bioactive multifunctional cytokine which 
promotes the accumulation of myeloid derived suppressor cells (MDSC) and 
increased the migration of pancreatic cancer cells via STAT-3 pathway [170, 171]. 
Our validated results agreed with the previous studies which have proven that IL-6 is 
secreted by PSCs [88] and is considered as the main regulator of 
immunosuppression in autoimmune diseases and cancer [139]. In the secretome of 
activated PSCs, both fibronectin and collagens are also highly upregulated. Recent 
studies indicated that PSCs are the main producer of ECM proteins in PDAC 
microenvironment [209]. Such ECM proteins can have different functions; fibronectin 
is known to induce macrophages migration [210]  whereas, increased collagen 
secretion is attributed to a rapid differentiation of monocytes to macrophages [211]. 
Moreover, the ECM proteins play critical roles in the tumor-stromal interactions in 
pancreatic cancer and form a barrier to chemotherapy [72].  
11.1.3. The IPA analysis of the PSC’s secretome 
Notably, the diseases or functions annotation by IPA analysis for the secreted 
proteins designated most of the secreted proteins are predicted to participate in the 
immune response of cells, antigen presenting cells activation, cell apoptosis, cellular 
growth and proliferation and transmigration of cells. Also, the downstream analysis 
showed that, the regulated proteins in the secretome of activated PSCs are 
particularly involved in macrophage activation, movement, migration and induction. It 
has already been shown that IL-1β, TNF-α and IL-6, which are upregulated in the 
secretome of activated PSCs, enhance the expression of GM-CSF which in turn 
stimulates immune cells response against pathogens [212]. However, GM-CSF may 
induce monocytes and macrophages to secrete mediators such as IL-10 and 
prostaglandin E2 (PGE-2) which are negatively affecting T-cells function [213, 214]. 
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Therefore, as discussed above, the secreted proteins by PSCs are actively involved 
in the stromal cross-talks in the PDAC microenvironment. It is also highly possible 
that these proteins are secreted in vivo and contribute to the initiation and progress of 
PDAC.  
11.1.4. Increased ROS and PDAC proliferation by PSCs 
Our results have shown that intracellular ROS are increased in the TNF-α-activated 
PSCs which is in accordance with the previous finding [194]. TNF-α is a known cell 
apoptosis or survival inducer [215] through inducing reactive oxygen species (ROS) 
production [194] thus, ROS could be considered as a marker for the activation of 
PSCs by TNF-α. Intracellular ROS can be measured using H2DCFDA (2′,7′-
dichlorodihydrofluorescein diacetate) which is non-fluorescent. The acetate group is 
cleaved by the intracellular esterases which is then converted to a highly fluorescent 
dye [216]. High ROS level is also expected when activated PSCs secret an elevated 
level of platelet-derived growth factor (PDGF) which activates the nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase enzymes [217]. Of note, 
increased ROS synthesis by the oxidative enzymes leads to the persistent activation 
of PSC [218]. It has been reported that ROS with the secreted growth factors and 
cytokines by activated PSCs participate in transforming chronic pancreatitis (CP) into 
cancer [219]. Nevertheless, ROS is a double-edged sword in physiological and 
pathological processes, for example, ROS at low concentrations could act as a 
signaling molecule in tumorigenesis but at high concentrations it is toxic and could 
exert apoptosis in cancer cells [220]. 
In the light of the important role of the PSCs in PDAC development and tumor size 
[83], we investigated the impact of PSCs secretome on the pancreatic cancer cells 
proliferation. Interestingly, our results show that the secretome of activated PSCs has 
significantly increased PDAC cell proliferation. It could be attributed to the differential 
regulation of different molecules associated to the cell proliferation. The analysis of 
PSC’s secretome using antibody microarrays shows several upregulated proteins 
which are associated to the increase in cell proliferation. Proteins such as,  
fibronectin [221], insulin-like growth factor 2 (IGF-2) [222], IL-4 [223], VEGF-C [224] 
and MMP-14 [225] have previously been attributed to the increased proliferation of 
different cancer cells. However, there are also proteins which are involved in intrinsic 
and extrinsic  apoptosis pathways, such as Bax, Bak [226], cytochrome C [227], 
caspase 8 [226] and IL-15 [228]. These proteins are downregulated in the secretome 
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of activated PSCs. Given these points, the increased cell proliferation can mainly be 
explained by the differential regulation of the mentioned markers in the PSCs 
secretome.  
One of the highly upregulated proteins in the secretome of activated PSCs is IL-6. 
Our results demonstrated that IL-6 has no significant effect on the proliferation of 
Panc-1 cells. This is possibly due to the multifunctional influence of IL-6 which has 
been shown to inhibit the proliferation of breast cancer cell [229] while on the 
contrary, IL-6 increased satellite cells and glioma cells proliferation through inducing 
syndecan-binding protein and activation of JAK2/STAT3 signaling pathway [230, 
231]. The IPA analysis of the activated PSCs secretome demonstrated that, 
apoptosis, necrosis and cell death are predicted to decrease whereas, in contrast, 
cell proliferation, survival, migration and invasion are increased. It has also been 
noted that, IL-6 induced the expression of VEGF on CFPAC-1 cells [232]. Also, 
higher serum level of IL-6 is considered as an independent risk factor and contributed 
to PDAC progression [233]. Hence, IL-6 may indirectly contribute to the cell 
proliferation via inducing growth factors and activating the relevant signaling 
pathways.  
 
11.2. Impact of PSCs secretome on monocyte differentiation and 
macrophages polarization 
11.2.1. Monocyte differentiation to macrophages 
The pancreatic tumor microenvironment is very complex where different cells, mainly 
PSCs and macrophages coexist with the tumor cells. To explain the cross-talk 
between PSCs and macrophages in pancreatic cancer, highly purified monocytes 
were isolated and treated with the secretome of PSCs. Monocytes are 
direct precursors of macrophages which polarize afterwards into classically activated 
(M1) or alternatively activated (M2) macrophages [234]. Monocyte’s differentiation 
into macrophages is accompanied by phenotypical changes however with some 
differences between M1 and M2 types in different environments [235].  
In our study, M1 positive macrophages are more elongated cells whereas M2 
macrophages have round-shaped structure but cells treated with the PSC’s 
secretome contain both cell types. Thus, no conclusion can be drawn based on the 
cell morphology because alteration in macrophages’ morphology is associated with 
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the changes in extracellular matrix [236]. Also, cell morphology is not merely 
associated with the expression of macrophage markers [237]. Therefore, the 
expression of HLA-DR marker [238] was analyzed on the treated macrophages. 
Interestingly, macrophages treated with the PSC secretome has expressed higher 
HLA-DR than the cells treated only with the priming factors M-CSF and GM-CSF. It is 
not well known yet, how HLA-DR is stimulated on macrophages, but studies suggest 
that IL-4, TGF-β, Prostglandin-E2 and IFN may increase HLA-DR on macrophages 
[237]. Also, HLA-DR expression is interleukin dependent, particularly IL-2, IL-4 and 
IL-12 [239]. Accordingly, increase of HLA-DR expression could be attributed to the 
elevated level of interleukins such as IL-2 and IL-4 in the secretome of PSCs. 
11.2.2. Macrophage polarization 
There are no established markers to define differences and similarities between M1 
and M2 macrophages, however, a few markers were considered to distinguish M1 
from M2 phenotype [110]. Polarization of macrophages is therefore categorized by 
the expression of special surface markers and regulation of certain cyto-chemokines.  
Expression of cell surface markers 
We have demonstrated that M2 markers, CD163 and CD206, were highly expressed 
on the macrophages which were treated with the secretome of activated PSC and 
PDAC (Figure 15).  This acts in accordance with what has been reported in PDAC 
tissues where CD163-positive macrophages were found primarily in the tumor stroma 
[240]. This finding indicates the role of the secreted signals by the tumor and stromal 
cells on macrophages. CD163 is induced by the anti-inflammatory signals such as IL-
6 and IL-10 [241] and it is attributed to the pro-tumoral activation of macrophages in 
sarcoma [242]. Notably, IL-6 and IL-10 are highly upregulated in the secretome of 
activated PSCs and PDAC cell lines respectively.  Above all, several studies have 
shown that, high numbers of CD163-positive macrophages are associated with 
advanced cancer stages, bad prognosis and reduced survival rate [243, 244]. Still, it 
is believed that CD163 is not restricted to M2 macrophages only, therefore it is not a 
reliable M2 marker when used alone [245]. Accordingly, we also measured the 
expression of mannose receptor (CD206) which is a type-I transmembrane 
glycoprotein and is a recognized M2 specific marker in human and mouse [246]. In 
normal tissues, CD206-positive macrophages involved in the resolution of 
inflammation whereas, in pathological conditions, they promote fibrosis [247]. In 
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tumors, mucins were shown to bind to CD206 and exert immunosuppressive 
properties of TAMs [248]. Of note, it is reported that TNF-α and IL-1β, which are 
secreted by the activated PSCs, induce the overexpression of mucin [249] hence 
they promote immunosuppression.  
In contrast, the expression of the M1-marker CD86 is reduced upon treatment with 
the secretome of the activated PSCs in comparison to the macrophages which were 
treated with the secretome of non-activated PSCs. This is in accordance with the fact 
that CD86 is required to bind to CD28 on the surface of T-cells to initiate an effective 
immune response and modulate the diseases [250]. CD86 is identical to CD80 and is 
stimulated by IFN- [251]. It is highly unlikely that macrophages gained M1 or M2 
phenotypes affected by the serum-free medium. Tarique et al. has demonstrated that 
polarized macrophages will revert back to the uncommitted M0 state when incubated 
in a cytokine-free medium for 12 days [252]. They have also reported that, 
macrophages could be switched from M1 to M2 and vice versa, when induced by the 
alternative polarizing stimulus. Accordingly, secreted proteins into the tumor 
microenvironment by the activated PSCs and tumor cells may switched and 
increased the number of CD163+ and CD206+ M2 macrophages, leading to the 
immunosuppression. 
RNA level of Cytokine and chemokines 
In addition to the cell surface markers, macrophage polarization was checked at the 
level of RNA by qRT-PCR based on the expression of specific cytokine and 
chemokines. Markers such as IL-1β and TNF-α, as M1 markers [110] or mannose 
receptor (CD206) and CCL17 as M2 markers [128] were analyzed in the treated 
macrophages. CD206 was checked again at the RNA level to validate the FACS 
data. Remarkably, the secretome of activated PSCs has significantly increased 
CD206 and CCL-17 on macrophages whereas, in opposite IL-1β and TNF-α are 
significantly reduced. The results clearly show the potent anti-inflammatory role of 
activated PSCs to modify macrophage’s response in the tumor microenvironment. 
The secretion of CCL17 by TAMs recruits T-regulatory cells (Treg) to the tumor, 
which in turn, they secret TGF-β, arginase and IL-10 to promote M2 polarization of 
macrophages with reduced antigen presenting ability and NO production [253, 254]. 
The proinflammatory cytokines IL-1β and TNF-α which are increased under the effect 
of non-activated PSCs secretome, are involved in tumor metastasis and invasiveness 
by promoting the expression of matrix metalloproteinases [255, 256]. Thus, based on 
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the present data, secretome of PSCs show promising effects on the activation state 
of macrophages in the tumor development.  
Arginase expression and NO production in the treated macrophages 
To distinguish between the two activation states of macrophages, metabolism of L-
arginine is thought to be a distinctive means [122]. Arginase-1 (Arg-1) is a key 
feature of M2 macrophages which contributes in wound healing and fibrosis by 
catalyzing arginine to urea and ornithine [122, 123]. Macrophage’s arginase activity 
and expression has significantly increased when treated with the conditioned medium 
of activated PSCs. Our results are consistent with the previous studies which showed 
that co-culture of fibroblasts and pancreatic cancer cells with monocytes, polarized 
monocytes to the M2 phenotype which highly expressed Arg-1 [257]. It was also 
shown that, Arg-1 is induced by exogenous Th2 cytokines such as IL-4 and IL-13 
through STAT-6 activation [125]. In contrast, recent studies suggested recombinant 
human arginase as therapeutic agent in treatment of non-Hodgkin's lymphoma [258], 
acute lymphoblastic leukemia [259], triple negative breast cancer [260] and 
glioblastoma [261] through blocking autophagy. Of note, autophagy is required for 
the activation of PSCs [262] hence, blocking the activation mechanism of PSCs could 
improve cancer treatment. 
On the other hand, L-arginine could be metabolized to nitric oxide (NO) and citrulline 
by induced nitric oxide synthase (iNOS), an enzyme which is highly expressed by M1 
macrophage [195]. As an indicator of iNOS enzyme, NO was measured in the 
conditioned media of the treated macrophages with the different PSCs secretome. 
Remarkably, the CM of activated PSCs have significantly suppressed NO production 
in macrophages. It could be suggested that, the increased expression of arginase in 
macrophages by the activated PSCs depleted arginine leading to the reduction of NO 
production by iNOS. In tumors, depending on its concentration, NO has both pro- and 
anti-tumor effects [116] for example, high NO production is the main weapon of 
macrophages against pathogens and tumors. It has been shown that NO inhibits T-
cell function by nitrating CD8 molecules and various proteins involved in T-cell 
receptor signaling [263]. Our results are supported by the findings of Cho et al. who 
found that, mesenchymal stem cells induce arginase activity in the adjacent 
macrophages but reduce iNOS [264]. They suggest that, macrophages shift from M1 
to M2 phenotype by the immune modulating characteristic of MSC. The same 
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mechanism however could be true for the role of activated PSCs secretome in 
switching macrophages to the M2 type. 
ROS synthesis in macrophages after treatment with the CM of PSCs 
Macrophages produce ROS that is needed for the uptake and clearance of apoptotic 
cells. However, maintaining high level of ROS may cause macrophage apoptosis 
during infection [265] and inhibit PDAC apoptosis [266]. In fact, ROS are attributed to 
the M2 polarization of macrophages [267] and the activation of PSCs [268]. 
Interestingly, the secretome of activated PSCs significantly decreased ROS synthesis 
in macrophages. This finding contradicts the results of Zhang et al. [196] who found 
that, monocytes treated with the CM of fibroblasts synthesize high amount of ROS 
which polarized macrophages towards the M2 type. Nevertheless, because activated 
PSCs induced Arg-1 activity and decreased NO production in the macrophages, 
therefore, it is highly expected that ROS is also decreasing. Thus, all the experiments 
indicate that the secretome of activated PSCs induce M2 polarization of 
macrophages.  
Role of PSC-educated macrophages in PDAC cell proliferation 
We have earlier shown that, the secretome of activated PSCs induced macrophages 
towards the pro-tumor M2 type. It has been shown that CAF-induced M2 
macrophages increased pancreatic cancer cell proliferation, migration and invasion 
[196]. Therefore, it is expected that the CM of the activated PSC-induced 
macrophages increase pancreatic cancer cell proliferation. The results agree with the 
findings of other studies as they demonstrated that M2 macrophages increase 
ovarian cancer cell proliferation via secreting EGFR and MMP-9 [198]. Taking into 
consideration, induced macrophages with the CM of non-activated PSCs didn’t inhibit 
cell proliferation although they highly expressed the M1 markers. This is however 
contradicting the findings of Engstrom et al. who demonstrated that CM of M1 
macrophages inhibit colon cancer cells [269]. Our data could suggest that non-
activated PSCs may induce M1 phenotype that have different characteristics and 
weaker anti-tumor activity. 
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11.2.3. Impact of IL-6 on macrophages pre and post-polarization 
As discussed above, the secretome of PSCs could be considered as the potent 
macrophage stimulants. Still, because of the high number of differentially regulated 
proteins in the secretome of PSCs and their quantity, it might be experimentally 
difficult to evaluate the role of each single molecule on macrophage polarization. The 
functional effect of some of the identified proteins have already been investigated on 
macrophage polarization. Molecules such as VEGF [270], TGF-β [271], IL-4 [272],  
are involved in macrophages M2 polarization. Whereas IFN- with LPS [273] and 
TNF-α [274] polarize macrophages towards M1 type. The M1 and M2 stimuli and the 
signals which influence their functional phenotypes are well reviewed  [110, 275]. 
IL-6 is one of the main pro-inflammatory factors which was upregulated in the 
activated PSCs secretome and has been studied in macrophages. Chomarat et al. 
reported that, IL-6 is switching the differentiation of monocytes from dendritic cells to 
macrophages, considering IL-6 as an essential factor in the molecular control of 
antigen presenting cells development [199]. It is also known that, IL-6 determines 
macrophage’s M2 polarization through IL-1β inhibition and regulation of excessive 
NO release [276].  Still, to our knowledge, the influence of IL-6 on macrophages 
before and after polarization is not studied.  
 Accordingly, on one hand, the macrophages were treated with the standard stimuli, 
IFN- / LPS and IL-4 with and without IL-6 to polarize to M1 and M2 macrophages, 
respectively. On the other hand, the previously polarized macrophages were then 
incubated with recombinant IL-6 followed by analyzing macrophage markers in each 
condition. Surprisingly, IL-6 shows different impacts on the expression of M1 and M2 
markers and the results were contradictory to each other. When IL-6 was used with 
the standard stimuli (pre-polarization), it didn’t affect M1 surface marker CD80, but in 
contrary, IL-6 decreased the expression of M2 surface markers, CD206 (Figure 23). 
In fact, this finding is consistent with the role of IL-6 where it is known that IL-6 
stimulates a range of signaling pathways to elicit inflammatory responses and 
eradicate pathogens [277]. But influence of IL-6 on the polarized macrophages was 
opposite to the pre-polarization results. When polarized macrophages were treated 
with IL-6, the expression of M2 marker CD206 was elevated on M1 and M2 types. 
Whereas, the M1 surface marker, CD80 was adversely affected by incubation with IL-
6 and was decreased on both macrophage phenotypes. These results interestingly 
suggest that, persistent release of inflammatory cytokines, such as IL-6, establishes 
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a tumor microenvironment which promotes switching macrophages from pro-
inflammatory to the anti-inflammatory type. However, the exact molecular pathway is 
not elucidated, but it has been proven that IL-6 increases the expression of IL-4 
receptor on macrophages which then induces M2 polarization after binding to IL-4 
[140]. It has also been shown that, continuous action of IL-6 in macrophages exerts 
the anti-inflammatory effects of IL-10 [278].These results may highlight the role of 
macrophages in the relationship between chronic pancreatitis and pancreatic cancer 
development [279]. Taken together, these results suggest that secretion of IL-6 by 
activated PSCs and immune cells at different stages of inflammation, may play 
different roles in macrophage polarization and as a result affecting immune response 
and tumor growth. 
11.2.4. Effect of IL-6 on arginase expression and NO synthesis 
The secretome of activated PSCs has increased arginase and reduced NO 
production. However, here we assess the impact of IL-6 on arginase and NO 
production which is one of the highly upregulated proteins in the activated PSCs 
secretome. The results show that arginase activity is increased by IL-6 but it is not 
significant in comparison to the non-treated macrophages whereas, IL-6 shows no 
significant impact on NO production. It has already been shown that IL-4/13 induce 
arginase activity and downregulate the production of NO in macrophages [280]. 
Nonetheless, when IL-6 was used with IL-4/13, arginase activity has significantly 
increased suggesting that, IL-6 increases the expression of IL-4rα on macrophages 
[281]. Therefore, it can be concluded that, role of IL-6 is situation dependent and it 
may also act as anti-inflammatory factor. IL-6 may exert its impact on arginase 
activity and NO synthesis but through enhancing the role of other molecules in the 
secretome of PSCs such as IL-4. 
11.2.5. Characterization of macrophages secretome and proteome 
To investigate the influence of PSCs secretome on the secretome and proteome 
profile of macrophages, THP-1 human monocytic cell line was used. Our results 
show that, the secretome samples of THP-1 macrophages are clearly clustered into 
two separate groups upon treatment with the secretome of PSCs. This additionally 
supports the obtained results by showing that, the secretome of PSCs had different 
impacts on the macrophage’s secreted molecules. Furthermore, the IPA analysis 
revealed that macrophages, which were treated with the CM of activated PSCs, 
Discussion 
91 
 
secret molecules which increase cell movement, cell to cell signaling and 
inflammatory response (Figure 26). These findings are agreed with the previous 
studies which reported that tumor associated macrophages (TAM) are producing 
high amount of CCL20 which recruits regulatory T-cells (Treg) and induce the 
recruitment of macrophage [282, 283]. The recruited macrophages will be exposed to 
the stromal cells and se findings explain the role of macrophages in cell to cell 
interaction, which in our study, is increased by the activated PSCs.  
The proteome analysis by IPA predicted the increase of transactivation, fibrosis and 
tumor invasion which are the hallmarks of pancreatic cancer. The IPA analysis 
predicted that the secretome of activated PSCs decrease the phagocytic function of 
macrophages. Even though macrophages are the main phagocytic cells, however, in 
the late stage of cancer, M2 macrophages are less phagocytic because of the 
downregulation of EGF receptor [284]. The finding suggested that IL-4 can 
transactivate EGF-R through releasing heparin binding EGF (HB-EGF) to mediate 
inhibitory feedback to M2 macrophages. Hence, increased IL-4 secretion by the 
activated PSCs could be attributed with the decreased phagocytosis. This highlights 
why the high number of immunosuppressive M2 macrophages is associated to the 
poor prognosis of PDAC and its short survival rate [128].  Therefore, it can be 
assumed that the activation of PSCs is the critical cellular transformation occurred in 
the tumor microenvironment that promotes immunosuppression through regulating 
macrophages polarization and inhibiting antigen presenting cells.   
11.3. Application of cancer cell secretome in PDAC diagnosis 
We have demonstrated the critical role of PSCs secretome in the cellular 
communications between PSCs and macrophages which could somehow explain the 
anti-inflammatory impact of activated PSCs on TAMs in pancreatic tumor 
microenvironment. Cell secretome has long been investigated in the cell to cell 
communication [165] and in  biomarkers identification [285]. However, the application 
of identified biomarkers in cancer diagnosis is not well studied. Therefore, we aimed 
to define possible biomarkers in the pancreatic cancer cells secretome which may 
lead to a better accuracy of PDAC diagnosis. It is proposed that cancer cell line 
secretome and proximal body fluids are preferred sources for biomarker discovery 
[286].  “Blood-based diagnosis could improve the outcome of therapy, even for a 
disease as deadly as PDAC. Applied to people, who are at risk of developing 
pancreatic cancer – for instance, patients who have undergone tumor resection, 
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familial cases, and individuals with specific genetic syndromes or predisposing 
diseases, such as chronic pancreatitis or diabetes – an improvement in diagnostic 
accuracy could have significant consequences on life expectancy and quality.  
Analyses of peripheral blood are predestined to such an end; studies with microRNA, 
circulating DNA and exosomes or proteins have been reported [31, 32, 287-290].” 
[180].   
11.3.1. The array quality and cell secretome analysis 
To improve the accuracy of protein-based diagnosis, we studied the secretome of 
tumor cells which represent the pathological condition as secretome specifically 
reflects the actual changes of diseased cells. In the analysis, a large panel of 
antibodies was applied. The antibodies cover target proteins that are associated to 
cancer according to KEGG and GO term annotation and their power for diagnosis of 
other tumors had been demonstrated [291, 292] also, they have previously been 
used in the analysis of the intracellular proteome of 24 pancreatic tumor cell lines 
[185]. Moreover, cell secretome has previously been studied, however using different 
techniques. “An earlier, mass spectrometry-based analysis of conditioned media of 
six tumor cells had reported 63 most differentially abundant molecules [293]. No 
overlap was found between them and the 112 molecules that we identified. This is 
not too surprising given the many differences between the studies. The criteria for 
selecting differentially abundant proteins were different; sample preparation was also 
very different. In addition, only about 15% of all detected proteins overlapped 
between the two studies. The reasons for this are the facts that the microarray 
analysis was biased by the availability of antibodies, but that its detection sensitivity 
is substantially higher. Therefore, the results are likely to be complementary.” [180]. 
11.3.2. Cancer cell secretome characterization 
“The fact that there was very little correlation of protein abundance in secretome and 
the related intracellular proteomes suggests that the secreted proteins are regulated 
independent of the intracellular protein expression. Similar data, although focusing on 
the protein content of exosomes released from colorectal cancer cells showed also a 
nearly inverse protein abundance in exosomes and intracellularly [294]. In view of 
these results, a transfer of tumor markers that were identified in tissues for an 
identification of disease in serum does not seem promising. The functional 
annotations of the 112 proteins that were found to differ in the secretome of tumor 
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and non-tumor cells indicated a potential role of secreted proteins as anti-apoptotic 
factors” [180]. Also, the analysis suggested an influence on immune cells which is 
consistent with the experimental finding as the secretome promotes macrophages 
polarization relatively higher towards the pro-tumor types. The macrophage 
phenotype which is attributed to the immunosuppression in PDAC due to the 
activation of STAT-3 in M2 macrophages and by secreting immunosuppressive 
cytokines IL-6 and IL-10 which are also associated to the poor survival of PDAC 
patients [295, 296]. Markedly, IL-10 is significantly upregulated in the pancreatic 
cancer cell lines secretome and PDAC serum. It is likely that several properties of 
PDAC are mediated by the interaction via secretory factors of the various cell types in 
the tumor microenvironment, of which tumor cells are only a part.  
11.3.3. Comparison of cell secretome to the related intracellular proteome 
The comparison of the secretome of PDAC cell lines with the relevant cellular 
proteome shows unique protein signatures with only 15% resemblance in their 
regulation most of which are attributed to the extracellular functions. “Surprisingly, the 
secretome analysis did not reveal any apparent correlation of secretome composition 
with the tumor cells’ original location – primary tumor, metastatic tumors or ascites – 
or the degree of differentiation, while the intracellular proteome had shown significant 
differences [185]. This suggests that it is unlikely to detect informative variations of 
this type in serum either, assuming that the serum acts as a combined representation 
of the various cell secretome. However, other cells of the respective 
microenvironment of primary tumors, metastatic tumor or ascites may well secrete 
protein signatures, which differ in their composition, and may permit serum-based 
diagnosis” [180]. 
11.3.4. Protein variations in patient serum samples 
“The 8 proteins that exhibited similar abundance differences in the serum and 
secretome profiles belong to the proteins that are most strongly regulated in terms of 
their abundance level in tumor secretome. One could speculate that they are 
therefore the ones most likely to remain detectable after becoming part of the serum. 
Other proteins may lose their discriminative power as they get diluted and obscured 
too much to remain informative. While for understanding tumor biology the 
identification of even subtle variations could be as important as that of large changes 
in expression, it could be advantageous for serum diagnostics to concentrate on 
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proteins, which in secretome analyses are present at high concentrations and exhibit 
large differences in expression. The value of comparing secretome analyses and 
serum studies for the definition of reliable biomarkers is demonstrated by the results 
obtained for protein GRPR, for example, which was implicated as a marker molecule 
[297]. In view of the contradictory results of the secretome and serum analysis, with 
GRPR being up-regulated in tumor cell secretome while down-regulated in PDAC 
patient serum, the reliability of the marker could be questioned. It cannot be excluded 
that it is a bona fide marker of high predictive value nevertheless and that the serum 
abundance reflects the overall release of the protein from other cell types in or 
around a tumor. However, as long as this is not evaluated in more detail, one should 
act carefully with utilizing GRPR as a marker in liquid biopsy” [180].  
11.3.5. Serum-based diagnostics and validation 
The diagnosis based on the sera yielded a signature of just eight proteins, which 
permitted the identification of PDAC patients with an accuracy of 95.1%. Some of the 
proteins, such as IL10, ID1 and IL2, had been implicated as possible biomarkers of 
pancreatic cancer before [298-300]. “However, the result sheds new light on the 
process by which marker molecules should be selected for a useful diagnostic 
signature. Compared to the other 181 serum markers, the eight molecules shared 
between secretome and serum do not show any particular discriminative 
performance individually. In combination, however, they beat any panel of eight 
markers made only from serum proteins by quite a margin. Actually, even adding up 
more serum markers could not yield a signature with a better diagnostic performance. 
In the comparison of PDAC and CP sera, the eight proteins were again not different 
from other markers individually. But also, as a signature, they were not superior to 
other panels. The reason for this could be the fact that they were identified in a 
secretome analysis, in which tumor and normal cells were compared to each other. 
This suggests that adding to a signature the apparently best individual markers may 
not yield the best possible signature. Instead, considering biological and functional 
data, such as variation in the secretion from different cell types, could contribute 
valuable information for selecting useful markers” [180]. 
 
Conclusions 
95 
 
12. Conclusions  
Understanding the stromal cells and cancer cells networking in the tumor 
microenvironment have become a hotspot in pancreatic cancer research. However, the 
alteration of PSCs activity and the interaction between PSCs and macrophages remain 
largely unclear. The present study demonstrates that TNF-α activates PSCs through 
increasing the expression of α-SMA and FN and augments the secretome profile of 
PSCs.  We demonstrated that activated PSCs increase the proliferation of pancreatic 
cancer cells, which was confirmed by analyzing the secretome content of the activated 
PSCs that contained proteins related to cancer cell proliferation such as VEGF-C, FN-1, 
MMP14 and IGF-2. This supports that, the secretome of activated PSCs are an 
important means of intercellular communication and have a considerable impact on 
PDAC development [301].  
in PDAC M2-polarized tumor associated macrophages (TAMs) were identified as the 
most prominent immune cell subpopulation which are associated with the poor 
prognosis and therefore were considered a good target for cancer therapy [128, 302]. 
The present study demonstrates how activated PSCs enhance the immunosuppression 
through the polarization of macrophages towards the pro-tumor phenotype. We have 
shown that, the secretome of activated PSCs induced the expression of CD163 and 
CD206 surface markers as well as increased arginase activity and inhibited NO and 
ROS production. Analyzing the downstream effect of activated PSCs revealed their 
immunosuppressive effects by secreting CCL17 and impairing the production of pro-
inflammatory cytokines IL-1β and TNF-α in macrophages. Interestingly, IL-6 enhances 
and sustains the polarization of M2 markers and could be attributed to the 
transformation of macrophages to the M2 type in chronic pancreatitis. Still, future studies 
are required to dissect the PSC-macrophage interaction and to unlock the barriers to 
therapies in pancreatic cancer. 
Identifying the origin of the secreted proteins and the characterization of their functional 
effects are key elements for understanding the dynamic changes in the tumor 
microenvironment during tumorigenesis. We, therefore, analyzed the common markers 
between the secretome of pancreatic cancer cells and serum of PDAC patients to 
identify suitable biomarkers for PDAC diagnosis. The identified markers EPHB3, FGF1, 
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ID1, IL2, IL10, IMPDH2, SELL, VCAM1, were analyzed in two different sample batches 
and they increased the accuracy of PDAC diagnosis compared to the patient’s serum 
samples only. However, the data shown here are an initial step of identifying suitable 
biomarkers of high accuracy and highlight the fact that cell secretome can be 
enormously helpful in this identification process. 
It can be concluded that, PSCs secrete massive amount of proteins into the tumor 
microenvironment which are mainly involved in stromal cell communications, such 
interactions may further establish favorable environment for tumor cells, increase anti-
inflammatory effects and tumor growth. However, because of the heterogeneity of PDAC 
microenvironment and sensitivity of macrophages to the stimuli in the tumor 
microenvironment, more investigation is necessary to understand the stromal cells 
interactions and identify better targets for therapy.  
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